<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31035684</article-id>
<article-id pub-id-type="pmc">6539237</article-id>
<article-id pub-id-type="doi">10.3390/ijms20092115</article-id>
<article-id pub-id-type="publisher-id">ijms-20-02115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Srikantha</surname>
<given-names>Piranavie</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2112-6281</contrib-id>
<name>
<surname>Mohajeri</surname>
<given-names>M. Hasan</given-names>
</name>
<xref ref-type="corresp" rid="c1-ijms-20-02115">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-02115">Department of medicine, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Switzerland; <email>piranavie.srikantha@uzh.ch</email></aff>
<author-notes>
<corresp id="c1-ijms-20-02115"><label>*</label>Correspondence: <email>mhasan.mohajeri@uzh.ch</email>; Tel.: +41-79-938-1203</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>9</issue>
<elocation-id>2115</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>New research points to a possible link between autism spectrum disorder (ASD) and the gut microbiota as many autistic children have co-occurring gastrointestinal problems. This review focuses on specific alterations of gut microbiota mostly observed in autistic patients. Particularly, the mechanisms through which such alterations may trigger the production of the bacterial metabolites, or leaky gut in autistic people are described. Various altered metabolite levels were observed in the blood and urine of autistic children, many of which were of bacterial origin such as short chain fatty acids (SCFAs), indoles and lipopolysaccharides (LPS). A less integrative gut-blood-barrier is abundant in autistic individuals. This explains the leakage of bacterial metabolites into the patients, triggering new body responses or an altered metabolism. Some other co-occurring symptoms such as mitochondrial dysfunction, oxidative stress in cells, altered tight junctions in the blood-brain barrier and structural changes in the cortex, hippocampus, amygdala and cerebellum were also detected. Moreover, this paper suggests that ASD is associated with an unbalanced gut microbiota (dysbiosis). Although the cause-effect relationship between ASD and gut microbiota is not yet well established, the consumption of specific probiotics may represent a side-effect free tool to re-establish gut homeostasis and promote gut health. The diagnostic and therapeutic value of bacterial-derived compounds as new possible biomarkers, associated with perturbation in the phenylalanine metabolism, as well as potential therapeutic strategies will be discussed.</p>
</abstract>
<kwd-group>
<kwd>Autism</kwd>
<kwd>ASD</kwd>
<kwd>microbiota</kwd>
<kwd>gut-brain-axis</kwd>
<kwd>microbiota-gut-brain-axis</kwd>
<kwd>probiotics</kwd>
<kwd>prebiotics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-02115" sec-type="intro">
<title>1. Introduction</title>
<p>The microbiota-gut-brain-axis describes the bidirectional physiological connection to exchange information between the microbiota, the gut and the brain [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>]. The gastrointestinal (GI) tract, the largest surface in the body, meets trillions of microorganisms separated by the gut barrier [<xref ref-type="bibr" rid="B2-ijms-20-02115">2</xref>]. The gut barrier is made out of the commensal gut microbiota, a mucus layer and epithelial cells connected through tight junctions [<xref ref-type="bibr" rid="B3-ijms-20-02115">3</xref>,<xref ref-type="bibr" rid="B4-ijms-20-02115">4</xref>]. A healthy microbial composition is important to health, as dysbiosis is often observed in gut-related diseases and conditions such as inflammatory bowel disease, irritable bowel syndrome, diabetes and obesity, but also in unconventional diseases such as acne, allergy, cardiovascular disease, stress, depression, Alzheimer’s disease, multiple sclerosis, Parkinson’s and autism spectrum disorder (ASD) [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>,<xref ref-type="bibr" rid="B6-ijms-20-02115">6</xref>,<xref ref-type="bibr" rid="B7-ijms-20-02115">7</xref>,<xref ref-type="bibr" rid="B8-ijms-20-02115">8</xref>,<xref ref-type="bibr" rid="B9-ijms-20-02115">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-02115">10</xref>,<xref ref-type="bibr" rid="B11-ijms-20-02115">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-02115">12</xref>]. Dysbiosis is an altered microbial composition favouring pathogenic microbes over beneficial ones in the gut. Knowing that dysbiosis at a young age affects health-status during later life, it is important to study the life-long impacts of compromised GI functions during childhood. </p>
<p>In addition to dysbiosis, GI symptoms are four times more prevalent in children with ASD compared to the normal population [<xref ref-type="bibr" rid="B13-ijms-20-02115">13</xref>]. A wide range of GI symptoms are found in these children, such as constipation, diarrhoea, bloating, abdominal pain, reflux, vomiting, gaseousness, foul smelling stools and food allergies [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>,<xref ref-type="bibr" rid="B14-ijms-20-02115">14</xref>,<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>,<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>,<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>,<xref ref-type="bibr" rid="B18-ijms-20-02115">18</xref>,<xref ref-type="bibr" rid="B19-ijms-20-02115">19</xref>]. In addition, lower bacterial diversity found in autistic children [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>,<xref ref-type="bibr" rid="B21-ijms-20-02115">21</xref>] could be related to the severity of GI symptoms [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>]. The higher abundance of <italic>Clostridia</italic> species (spp) in autistic individuals suggests involvement in the pathogenesis of ASD [<xref ref-type="bibr" rid="B22-ijms-20-02115">22</xref>]. Structural changes in the brain [<xref ref-type="bibr" rid="B23-ijms-20-02115">23</xref>,<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>,<xref ref-type="bibr" rid="B25-ijms-20-02115">25</xref>,<xref ref-type="bibr" rid="B26-ijms-20-02115">26</xref>,<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>,<xref ref-type="bibr" rid="B28-ijms-20-02115">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-02115">29</xref>,<xref ref-type="bibr" rid="B30-ijms-20-02115">30</xref>] and less sociable behaviours [<xref ref-type="bibr" rid="B31-ijms-20-02115">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-02115">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-02115">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-02115">34</xref>] observed in germ-free mice indicate a functional connection between the microbiota and the brain. However, as there are major differences between the murine and the human microbiota [<xref ref-type="bibr" rid="B35-ijms-20-02115">35</xref>], the validity of drawing conclusions from GF mice to humans is limited. Nevertheless, the observed behavioural changes in germ-free mice raise the question regarding the mechanisms of action of microbiota on human metabolism.</p>
<p>The frequently reported comorbidity of GI problems in autistic children [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>,<xref ref-type="bibr" rid="B14-ijms-20-02115">14</xref>,<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>,<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>,<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>,<xref ref-type="bibr" rid="B18-ijms-20-02115">18</xref>,<xref ref-type="bibr" rid="B19-ijms-20-02115">19</xref>] motivated the central question of this review: is there a connection between the gut microbiota and the central nervous system (CNS) affecting the pathology of ASD? This is an important question considering that only approximately one third of all autistic cases could be linked to genetic causes [<xref ref-type="bibr" rid="B36-ijms-20-02115">36</xref>]. Furthermore, no satisfactory effective treatment is available for Autism Spectrum Disorder to date. Therefore, understanding and modulating the microbiota-gut-brain-axis may be an effective and promising way for ameliorating the disease symptoms [<xref ref-type="bibr" rid="B37-ijms-20-02115">37</xref>]. The objective of this review is to summarize all peer-reviewed human studies and reviews on the topic connecting gut microbiota with ASD and suggesting metabolites, which could serve as potential biomarkers after further validation. The elevation of 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid in autistic children hinted to perturbation in the phenylalanine metabolism [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>]. These metabolites are related to the abundance of <italic>Clostridia</italic> spp which worsens autistic behaviour [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>].</p>
</sec>
<sec id="sec2-ijms-20-02115">
<title>2. Material and Methods</title>
<p>In this systematic review we concentrated on the question: Is there a connection between the gut microbiota and the central nervous system (CNS) affecting the pathology of ASD? PubMed databank and online books were searched on February 1st 2018. The objective was to study the possible connection between the microbiota/microbiome and ASD. The following search parameters and MeSH terms “Microbiome”, “microbiota”, “gut-brain-axis”, “autism”, “autistic disorder” and “human” delivered 139 hits (<xref ref-type="fig" rid="ijms-20-02115-f001">Figure 1</xref>). </p>
<p>We concentrated on bacterial taxa excluding excluded citations regarding viruses and archaea. Thus, inclusion criteria were the following: <list list-type="simple"><list-item><label>-</label><p>Diagnosis of ASD by medical experts</p></list-item><list-item><label>-</label><p>Human studies of the microbiome or metabolome in autistic individuals</p></list-item><list-item><label>-</label><p>ASD individuals were compared to a matched control group</p></list-item><list-item><label>-</label><p>Collection and analysis of at least one of the following biomaterials: GI biopsies, faecal, urinary or blood samples</p></list-item><list-item><label>-</label><p>Analysis of bacterial genome by sequencing</p></list-item><list-item><label>-</label><p>Published in a peer-reviewed article</p></list-item><list-item><label>-</label><p>Availability of the full text publication</p></list-item><list-item><label>-</label><p>Availability of the paper in English</p></list-item></list></p>
<p>Most of the examined papers were published between 2013 and 2018. The evaluation of literature was conducted by two independent researchers resulting in the same included papers. Seven papers were excluded as full texts were not available. Five non-English papers were excluded, and five papers were excluded due to the lack of any relevance to the topic. In total, 136 papers were examined for this systematic review. Online books were used for the definitions of diseases.</p>
</sec>
<sec id="sec3-ijms-20-02115">
<title>3. Comorbidities in Autism Spectrum Disorder</title>
<sec id="sec3dot1-ijms-20-02115">
<title>3.1. Definition</title>
<p>Autism spectrum disorder (ASD) is a collective term for autism, Asperger’s syndrome and pervasive developmental disorder not otherwise specified [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. More male than female individuals are affected by the disease [<xref ref-type="bibr" rid="B41-ijms-20-02115">41</xref>,<xref ref-type="bibr" rid="B42-ijms-20-02115">42</xref>]. The prevalence of ASD was one in fifty-nine children in the United States in 2014 [<xref ref-type="bibr" rid="B43-ijms-20-02115">43</xref>,<xref ref-type="bibr" rid="B44-ijms-20-02115">44</xref>]. Autistic behaviour is characterized by poor communication skills, social withdrawal, repetitive or restrictive pattern in behaviour, interests and activities and the onset of these diagnostic features in early developmental stage [<xref ref-type="bibr" rid="B45-ijms-20-02115">45</xref>]. Other reported behaviour are picky eating habits [<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>,<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>,<xref ref-type="bibr" rid="B46-ijms-20-02115">46</xref>], increased aggression [<xref ref-type="bibr" rid="B47-ijms-20-02115">47</xref>] and anxiety [<xref ref-type="bibr" rid="B48-ijms-20-02115">48</xref>]. Regressive autism or late onset autism describes a subgroup of patients with initially normal development but with a gradual loss of acquired skills in communication or social interaction [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Asperger’s Syndrome manifests next to social withdrawal with superior cognitive skills. The phenotypes of ASD are heterogeneous, suggesting that many factors play into the aetiology [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. Both genetic and environmental factors are implicated in ASD but most cases of ASD are idiopathic [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>]. Lastly, abnormal eating habits are frequently reported in autistic individuals, possibly leading to deficiencies in vitamins, minerals and fatty acids [<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>].</p>
</sec>
<sec id="sec3dot2-ijms-20-02115">
<title>3.2. Gastrointestinal Symptoms</title>
<p>Several comorbidities are frequently reported in ASD children (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>). GI problems are often observed in autistic individuals [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>,<xref ref-type="bibr" rid="B14-ijms-20-02115">14</xref>,<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>,<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>,<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>,<xref ref-type="bibr" rid="B18-ijms-20-02115">18</xref>,<xref ref-type="bibr" rid="B19-ijms-20-02115">19</xref>]. In a small sample size including ten autistic children, nine non-autistic siblings and ten healthy children severity and number of GI symptoms were found to be significantly higher in autistic children and their siblings compared to healthy controls [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]. Accordingly, a different bigger study comparing 230 pre-schoolers discovered similar results. ASD patients were suffering significantly more often from GI problems than healthy controls. ASD patients with GI symptoms were found to have more anxiety problems and other somatic complaints in addition to less social interaction in comparison to ASD patients without GI problems [<xref ref-type="bibr" rid="B14-ijms-20-02115">14</xref>]. Constipation was found to be the most common GI symptom observed in autistic children. The same authors also found a connection between rigid-compulsive behaviour and the occurrence of constipation [<xref ref-type="bibr" rid="B13-ijms-20-02115">13</xref>]. Additionally, GI problems in autistic children were reported to lead to more tantrums, aggressive behaviour and sleep disturbances, further worsening the behaviour compared to autistic individuals without GI symptoms [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>]. One review suggested that altered behaviour such as aggression, self-injury or sleep disorder observed in autistic children might be an expression of abdominal discomfort [<xref ref-type="bibr" rid="B50-ijms-20-02115">50</xref>].</p>
<p>Autistic children show an altered metabolism and absorption of disaccharides in their gut epithelium (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>,<xref ref-type="bibr" rid="B51-ijms-20-02115">51</xref>]. The disaccharidases in the brush border of the ileum such as lactase, maltase glucoamylase and sucrose isomaltase, were found to have lower mRNA levels and hence a decreased gene expression [<xref ref-type="bibr" rid="B52-ijms-20-02115">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. The sodium-dependent glucose cotransporter (SGLT1) and the glucose transporter 2 (GLUT2) transport glucose, galactose and fructose actively across the luminal and basolateral membranes of the enterocytes. Autistic children were reported to exhibit significantly decreased mRNA levels of both hexose transporters in the ileum [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. Consequently, there is a malabsorption in the small intestine and more mono- and disaccharides enter the large intestine. Thus, bacteria fermenting these low-molecular sugars profit and outcompete bacteria degrading polysaccharides leading to an altered microbial composition in the GI tract. Higher amounts of sugars in the large intestine could lead to osmotic diarrhoea or these sugars could serve as substrates for the production of gases [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. Diarrhoea and bloating are both GI symptoms observed in ASD patients. GI symptoms in ASD patients are known to correlate with the severity of autistic behaviour [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>].</p>
</sec>
<sec id="sec3dot3-ijms-20-02115">
<title>3.3. Increased Gut Permeability</title>
<p>An increased intestinal permeability was observed in ASD patients (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>) by measuring lactulose in blood after oral administration [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>]. Autistic children as well as their non-autistic siblings were found to have increased gut permeability compared to controls [<xref ref-type="bibr" rid="B54-ijms-20-02115">54</xref>]. Increased gut permeability is probably a result of decreased expression of barrier forming proteins and the elevated expression of pore forming proteins of tight junctions. These altered expressions were found by analysing mucosal samples from the small intestine of autistic children compared to controls [<xref ref-type="bibr" rid="B55-ijms-20-02115">55</xref>]. Changed permeability could lead back to lower counts of <italic>Lactobacillus</italic> strains in autistic patients, as they are associated with the maintenance of tight junction in the epithelial barrier of the intestines [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>]. Bacterial metabolites, such as LPS, can easily pass the intestinal barrier and cause an inflammation affecting the brain through altering cytokine levels [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>]. Increased intestinal permeability was also found in some close non-autistic relatives of autistic individuals, suggesting that intestinal integrity is not a consequence of ASD. Rather, increased gut permeability should be viewed as a cause, which could in combination with other environmental factors, at least partially, lead to the pathology of ASD [<xref ref-type="bibr" rid="B56-ijms-20-02115">56</xref>].</p>
</sec>
<sec id="sec3dot4-ijms-20-02115">
<title>3.4. Alterations in the Brain</title>
<p>The analysis of post-mortem brains of autistic patients revealed altered expression of some claudines (CLDN) in the blood-brain-barrier (BBB) of the cortex and cerebellum. Significant changes were observed in the expression of the genes of CLDN-5 and CLDN-12. These two major constituents of tight junctions were overexpressed in the cortex and cerebellum of autistic children compared to controls (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>). CLDN-5 is an important protein in tight junctions for cell adhesion of endothelial cells in the brain. However, the protein expression of CLDN-12 was significantly reduced in the cortex of autistic children even though the gene was overexpressed [<xref ref-type="bibr" rid="B55-ijms-20-02115">55</xref>]. The over-expressions of the genes are suggestive of either a higher integrity of the BBB in autistic children or a compensatory mechanism to uphold the integrity of the BBB. The second explanation appears more plausible, as an increased destruction of the protein CLDN-12 could lead to an over-expression of the CLDN-12 gene and other tight junction components such as CLDN-5. These results suggest a lower integrity of the BBB leading to a compensatory overexpression of tight junction components. </p>
<p>Increased activation of microglial cells and other structural changes have also been observed post-mortem in the brains of autistic individuals (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>,<xref ref-type="bibr" rid="B57-ijms-20-02115">57</xref>]. The increase in activation of microglial cells suggests that ASD is a pathology caused or at least accompanied by immune activation in the brain. Inflammation in the brain could subsequently lead to malfunctioning synapses [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. During inflammation the brain releases arginine vasopressin, a metabolite, which is known to act on social behaviour and is a considered biomarker for ASD [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. A structural change was the increased weight of ASD brains possibly due to the presence of a larger number of neurons in the prefrontal cortex [<xref ref-type="bibr" rid="B57-ijms-20-02115">57</xref>]. Moreover, Purkinje cells are found in decreased numbers in the cerebellum of ASD patients [<xref ref-type="bibr" rid="B43-ijms-20-02115">43</xref>,<xref ref-type="bibr" rid="B58-ijms-20-02115">58</xref>]. Purkinje cells produce GABA, which makes them vulnerable to the tetanus neurotoxin produced by <italic>Clostridia tetani</italic> [<xref ref-type="bibr" rid="B43-ijms-20-02115">43</xref>]. Elevated amounts of <italic>Clostridia</italic> spp is reported in ASD, thus could account for decreased Purkinje cells in the cerebellum of ASD individuals.</p>
<p>There is a bidirectional relationship between the gut and the brain including among others vagal fibers [<xref ref-type="bibr" rid="B59-ijms-20-02115">59</xref>]. Enteroendocrine cells in epithelial barrier of the gut can sense the composition of the lumen such as nutrients and bacterial metabolites. These cells synapse with afferent vagal fibres, thus directly connecting the intestinal milieu with the brainstem [<xref ref-type="bibr" rid="B60-ijms-20-02115">60</xref>]. Peripheral stimulation of vagal fibres leads to a dopamine release in the reward system, as was shown in vivo [<xref ref-type="bibr" rid="B61-ijms-20-02115">61</xref>].</p>
</sec>
<sec id="sec3dot5-ijms-20-02115">
<title>3.5. Mitochondrial Dysfunction</title>
<p>Mitochondrial dysfunction was detected in ten ASD children (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>) comparing intestinal mucosa samples of rectum und caecum with that of ten Crohn’s disease children (representing non-autistic children with GI symptoms) and ten healthy children [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. ASD children displayed lower activity of the electron transport chain (ETC) enzyme complex IV and citrate synthase in mucosal samples taken both from rectum and caecum. In addition, they also showed significantly higher quantity of ETC complex I in the mucosa of the caecum. The quantities of the ETC enzyme belonging to complexes III, IV and V were only significantly increased in the caecum [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. The occurrence of these changes only in the caecum and not also in rectum is intriguing. Especially so, since the rectum acts as a transition passage, whereas the caecum inhabits many bacteria species. The authors discuss their finding stating that the altered expression of these enzymes, all involved in the energy production, leads to mitochondrial dysfunction. Mitochondrial dysfunctions disrupt normal functioning of enterocytes and therefore cause gut-dysmotility and higher sensitivity to oxidative stress. Increased oxidative stress results in damaged proteins and lipids in the cell and consequently causes diminished function of enterocytes. This suggests that bacterial metabolites may affect mitochondrial function in the caecum. SCFAs produced by <italic>Clostridia</italic> species spp could enter the mitochondria and be utilized as substrates for energy production [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. For example, butyrate is converted into acetyl-CoA, which then is utilized in the citric cycle for NADH production. NADH, on the other hand, is a substrate for ETC complex I, which could be the factor elevating its activity. Additionally, gut-dysmotility caused by mitochondrial dysfunction would explain constipation observed in autistic individuals [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. The occurrence of many GI problems observed in autistic children could partially be explained by gut-dysmotility. Interestingly, GI problems similar to that of autistic children have also been noted in children with mitochondrial dysfunction [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>], again suggesting a link between mitochondrial dysfunction, GI problems and microbiota in ASD individuals. </p>
</sec>
</sec>
<sec id="sec4-ijms-20-02115">
<title>4. Factors Influencing the Gut Microbiota</title>
<sec id="sec4dot1-ijms-20-02115">
<title>4.1. Definitions and Facts</title>
<p>The term microbiota describes the entirety of all bacterial, archaeal and fungal microorganisms living on the skin, in the mouth, in the respiratory, GI and vaginal tracts [<xref ref-type="bibr" rid="B37-ijms-20-02115">37</xref>]. As the term microbiota describes all microorganisms living in and on humans, the term microbiome describes all the genes expressed in all these microorganisms [<xref ref-type="bibr" rid="B50-ijms-20-02115">50</xref>]. The highest diversity of microbiota is found in the large intestine [<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>]. Approximately 1000 different spp of bacteria are reported to live in the GI tract [<xref ref-type="bibr" rid="B63-ijms-20-02115">63</xref>]. Healthy gut microbiota interacts with the human metabolism by educating the immune system, protecting against pathogenic microbes, metabolising non-digestible carbohydrates, producing essential vitamins and antimicrobial substances, stimulating angiogenesis and importantly reinforcing the gut barrier through increased mucine production [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>,<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B64-ijms-20-02115">64</xref>,<xref ref-type="bibr" rid="B65-ijms-20-02115">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-02115">66</xref>,<xref ref-type="bibr" rid="B67-ijms-20-02115">67</xref>]. The microbial composition varies through age, diet, diseases, geography [<xref ref-type="bibr" rid="B37-ijms-20-02115">37</xref>,<xref ref-type="bibr" rid="B68-ijms-20-02115">68</xref>] and shared environment [<xref ref-type="bibr" rid="B34-ijms-20-02115">34</xref>]. </p>
</sec>
<sec id="sec4dot2-ijms-20-02115">
<title>4.2. Developmemt and Disruptions of Microbial Colonisation in Autism</title>
<p>Colonisation of the GI tract with microbiota starts prenatally as microorganisms have been detected in the placenta and meconium [<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>,<xref ref-type="bibr" rid="B28-ijms-20-02115">28</xref>,<xref ref-type="bibr" rid="B69-ijms-20-02115">69</xref>,<xref ref-type="bibr" rid="B70-ijms-20-02115">70</xref>]. Moreover, some bacterial species of <italic>Enterococcus</italic>, <italic>Streptococcus</italic> and <italic>Staphylococcus</italic> were found in the blood of the umbilical cord. This suggests a transfer of microbiota from the mother to the foetus [<xref ref-type="bibr" rid="B71-ijms-20-02115">71</xref>]. A new-born shows an instable and highly dynamic intestinal microbiota with less microbial diversity and a dominance of the phyla Proteobacteria in the gut. With time, the diversity and colonisation increase and the dominance in Firmicutes and Bacteroidetes can be observed. [<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>]. First colonisers of healthy new-borns are <italic>Enterobacteria</italic>, <italic>Staphylococcus</italic> and <italic>Streptococcus</italic> spp, which are facultative anaerobes. These bacteria consume the oxygen in the gut and create an anaerobic environment. Following these first colonisations strict anaerobes as <italic>Bacteroides</italic>, <italic>Bifidobacterium</italic> spp and <italic>Clostridium</italic> spp can colonise the gut [<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>]. The composition of the microbiota stabilises around the age of 2–3 years [<xref ref-type="bibr" rid="B17-ijms-20-02115">17</xref>,<xref ref-type="bibr" rid="B73-ijms-20-02115">73</xref>]. Interestingly the brain of neonates also grows from 36% to approximately 90% of its future adult volume until the age of two. Also, the formation of new synapses in the brain peaks between the age of three months and two years [<xref ref-type="bibr" rid="B26-ijms-20-02115">26</xref>]. Thus, the critical window for establishment of a healthy microbial composition falls into the same critical time window for brain development [<xref ref-type="bibr" rid="B26-ijms-20-02115">26</xref>]. The developing brain is sensitive to many external and internal environmental factors. Therefore, it is postulated that changes in prenatal maternal stress level, infections or diet can play a role in the pathophysiology of neurodevelopmental disorders [<xref ref-type="bibr" rid="B71-ijms-20-02115">71</xref>,<xref ref-type="bibr" rid="B74-ijms-20-02115">74</xref>]. </p>
<p>Preterm birth, mode of delivery and breastfeeding influence the gut microbial composition of neonates. Vaginally born babies who are breastfed have the healthiest composition of microbiota. Beneficial bacteria such as <italic>Bifidobacteria</italic> are more abundant in these babies than pathogenic bacteria including <italic>Clostridium difficile</italic> or <italic>Escherichia coli</italic> [<xref ref-type="bibr" rid="B75-ijms-20-02115">75</xref>]. Human breast milk promotes the growth of <italic>Bifidobacterium longum</italic> [<xref ref-type="bibr" rid="B69-ijms-20-02115">69</xref>]. Vaginally born babies have a microbiota that resembles vaginal microbiota composition of the mother with dominance of <italic>Lactobacillus</italic>, <italic>Prevotella</italic> and <italic>Snethia</italic> spp [<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>]. Neonates born via caesarean section have an altered microbiota composition resembling the microbiota of the mother’s skin with dominance of <italic>Staphylococcus</italic>, <italic>Corynebacterium</italic>, <italic>Propionibacterium</italic> spp [<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>,<xref ref-type="bibr" rid="B77-ijms-20-02115">77</xref>], <italic>Escherichia coli</italic> and <italic>Clostridium difficile</italic> [<xref ref-type="bibr" rid="B78-ijms-20-02115">78</xref>]. Exclusively breastfed infants display also richness in <italic>Bifidobacterium</italic> spp, which are specialised in digesting oligosaccharides contained in human milk [<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>]. A study found that autistic children experienced significantly shorter period of breastfeeding [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>]. Preterm born babies possess low levels of gastric acidity, as GI functions have not fully matured. Consequently, more pathogenic microbes survive the stomach and can colonise the intestines leading to an accumulation of pathogenic microbiota and diminished degree of microbiome diversity in the GI tract [<xref ref-type="bibr" rid="B6-ijms-20-02115">6</xref>]. They display dominance in Proteobacteria and lack in the genera <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> [<xref ref-type="bibr" rid="B73-ijms-20-02115">73</xref>].</p>
<p>Using information from a population-based registry with approximately 2.6 million children, a Swedish study noted that elective caesarean births in comparison to natural vaginal delivery is associated with a significantly 20% higher risk of the child developing ASD [<xref ref-type="bibr" rid="B80-ijms-20-02115">80</xref>]. In contrast, no association was found in the sibling control analysis, so the authors concluded that there was no link between caesarean birth and ASD at all [<xref ref-type="bibr" rid="B80-ijms-20-02115">80</xref>]. Similarly, another cohort study from the UK with over 18,000 participants also found no association found between caesarean birth and development of ASD [<xref ref-type="bibr" rid="B81-ijms-20-02115">81</xref>]. </p>
<p>Antibiotic treatment during the first three years of life can have detrimental effect on normal microbiota establishment with long-term effects [<xref ref-type="bibr" rid="B82-ijms-20-02115">82</xref>]. It is known that many autistic children take relatively high doses of oral antibiotics in early years of life, which could be a factor disturbing their gut microbiota [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>]. Recovery of the microbiota to the pre-treatment state is incomplete even several months after the cessation of the treatment [<xref ref-type="bibr" rid="B37-ijms-20-02115">37</xref>]. Early treatment of infants with antibiotics can therefore disrupt the colonisation of gut with beneficial bacteria [<xref ref-type="bibr" rid="B73-ijms-20-02115">73</xref>]. Changes in the composition of the microbiota could lead to a leaky gut or increased passage of metabolites such as LPS or SCFAs through intestinal barrier [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>,<xref ref-type="bibr" rid="B83-ijms-20-02115">83</xref>], leading to the activation of an inflammatory response through binding to Toll-like receptor 4 also affecting the CNS [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>].</p>
<p>Maternal infection during pregnancy can lead to a modified microbial composition as well as an increased risk of ASD. Women were found to have a higher risk of carrying out autistic children, when they were hospitalised due to an infection during pregnancy. Interestingly, the risk for ASD was higher when infection occurred during a critical time window of development. Viral infections in the first trimester of the pregnancy and bacterial infections in the second trimester were associated with a higher risk of birthing autistic children [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. These data are in agreement with results obtained in maternal immune activated (MIA) mice. Pregnant mice were injected with polyinosinic:polycytidylic acid (poly(I:C)) to simulate viral infections. The offspring displayed altered microbial composition, GI barrier defects and behaviour similar to autistic features [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]. Elevated levels of cytokines in maternal blood were proposed to be the causing factor as poly(I:C) is also a cytokine [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]. Elevated levels of IL-6 were found in the colon from MIA mice [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]. The cytokine IL-6 is known to alter the expression of tight junction proteins, as it is proinflammatory, thus helping white blood cells to migrate through epithelial barriers [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]. Hence, the increased gut permeability in autistic children could be a consequence of immune activation in the GI tract [<xref ref-type="bibr" rid="B84-ijms-20-02115">84</xref>,<xref ref-type="bibr" rid="B85-ijms-20-02115">85</xref>]. Bacteroides, Bifidobacterium spp and Lactobacillus spp create an anti-inflammatory milieu, whereas Clostridium spp stimulate a pro-inflammatory milieu [<xref ref-type="bibr" rid="B86-ijms-20-02115">86</xref>]. Cytokines produced by microbiota affected the oligodendrocytes functioning [<xref ref-type="bibr" rid="B23-ijms-20-02115">23</xref>]. Therefore, an inflammation during pregnancy can result in alteration of myelination in the brain and possibly in behavioural changes, as observed in ASD [<xref ref-type="bibr" rid="B23-ijms-20-02115">23</xref>]. </p>
<p>Taken together, a higher risk for developing ASD was observed in children (i) who were born pre-term with a very low birth-weight [<xref ref-type="bibr" rid="B69-ijms-20-02115">69</xref>], (ii) who were born by caesarean delivery, (iii) who were not breastfed, (iv) who underwent prolonged hospitalization, (v) who were treated with antibiotics for a long period [<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>] or (vi) whose mothers had an infection during pregnancy [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. </p>
</sec>
</sec>
<sec id="sec5-ijms-20-02115">
<title>5. Alterations in Microbial Composition and Metabolic Profile in Autistic Individuals</title>
<sec id="sec5dot1-ijms-20-02115">
<title>5.1. Changes in Microbial Composition in Autistic Children</title>
<p>A regularly observed phenomenon in the faeces of autistic children is a significantly decreased ratio between the phyla Bacteroidetes to Firmicutes [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>,<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>,<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>,<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>], which pointed to elevated numbers of Firmicutes in contrast to decreased levels of Bacteroidetes. Conflicting data were reported by De Angelis et al., who found in a study with thirty subjects that Firmicutes counts were lower than Bacteroidetes in autistic children when compared to healthy controls [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. These results, however, were not statistically significant [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Moreover, the phyla Fusobacteria and Verrucomicrobia were also represented in lower concentrations (<xref ref-type="fig" rid="ijms-20-02115-f003">Figure 3</xref>) in the faeces of ten autistic children compared to ten healthy controls [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Significantly elevated bacteria in autistic children were <italic>Akkermansia muciniphila</italic>, <italic>Anaerofilum</italic>, <italic>Barnesiella intestinihominis</italic>, <italic>Clostridium</italic> spp, <italic>Dorea</italic> spp, the family Enterobacteriaceae, <italic>Faecalibacterium</italic> spp (especially <italic>Faecalibacterium prausnitzii</italic>), <italic>Roseburia</italic> spp, <italic>Parasutterella excrementihominis</italic>, <italic>Prevotella copri</italic>, <italic>Prevotella oris</italic> and <italic>Turicibacter</italic> spp. <italic>Escherichia coli</italic> was significantly decreased in autistic children [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Other higher represented spp were <italic>Aeromonas</italic>, <italic>Odirobacter splanchnicus</italic>, <italic>Parabacteroides</italic>, <italic>Porphyromonas</italic>, <italic>Pseudomonas</italic>, and <italic>Turicibacter sanguinis</italic>. Significantly decreased bacteria in autistic children were <italic>Bifidobacterium</italic>, <italic>Fusobacterium</italic>, <italic>Oscillospira</italic>, <italic>Sporobacter</italic>, <italic>Streptococcus</italic> and <italic>Subdoligranulum</italic>. Lower represented genera in autistic children were <italic>Collinsella</italic> spp except <italic>Collinsella aerofaciens</italic>, <italic>Enterococcus</italic> spp, <italic>Lactobacillus</italic>, <italic>Lactococcus</italic> and <italic>Staphylococcus</italic> [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Kang et al. compared the intestinal flora of twenty autistic children with GI problems to the intestinal flora of twenty neurotypical children. They found that the significant lower bacterial diversity found in autistic children [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>,<xref ref-type="bibr" rid="B21-ijms-20-02115">21</xref>] correlates with the severity of GI symptoms. No major differences were detected at phylum levels; however, this discrepancy could be a result of the parents collecting and freezing the stool samples and not the research team. Non-autistic children had a significantly higher abundance of the genus <italic>Coprococcus</italic> and class Prevotellaceae compared to autistic faecal samples. <italic>Prevotella</italic> spp are commensal gut microbes, specialised in degrading plant polysaccharides and synthesising vitamin B1. Lower abundance of <italic>Prevotella</italic> spp could therefore result in a vitamin B1 deficiency. In addition, Veillonellaceae were found in lower abundance in autistic children. Small differences were observed in <italic>Sutterella</italic> genus, being less abundant in autistic children [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>]. These data reveal a change in microbiota composition in autistic children that may have biochemical and functional consequences on the host. </p>
<p>Intestinal biopsies from the caecum and the terminal ileum of twenty-three ASD children showed significantly increased numbers of <italic>Sutterella</italic> spp compared to nine healthy controls. <italic>Sutterella</italic> spp are normally scarce in a healthy microbiota and were found in none of the controls, but in twelve of the twenty-three ASD patients [<xref ref-type="bibr" rid="B88-ijms-20-02115">88</xref>]. The microbial composition was also studied in duodenal biopsies comparing nineteen autistic children with twenty-one healthy controls [<xref ref-type="bibr" rid="B89-ijms-20-02115">89</xref>]. The study did not find any major differences between the phyla, but some alterations were observed at genus und species levels. The genus <italic>Burkholderia</italic> was significantly increased in autistic participants compared to controls. The genera <italic>Actinomyces</italic>, <italic>Oscillospira</italic>, <italic>Peptostreptococcus</italic> and <italic>Ralstonia</italic> were elevated and the genus <italic>Neisseria</italic> was significantly under-represented in autistic children compared to controls. The genera <italic>Bacteroides</italic>, <italic>Devosia</italic>, <italic>Prevotella</italic> and <italic>Streptococcus</italic> were also decreased. Also, lower abundances of <italic>Escherichia coli</italic> were observed [<xref ref-type="bibr" rid="B89-ijms-20-02115">89</xref>]. Kushak et al. could not find major differences at phylum level as above-mentioned studies [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>,<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>,<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>,<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. This could be due to the fact, that all the other studies investigated microbial composition from stool samples and not biopsies from duodenal mucosa. The stool samples represent, by and large, microbial composition of the large intestine [<xref ref-type="bibr" rid="B90-ijms-20-02115">90</xref>]. Kushak et al., on the other hand, represented microbial composition of the small intestine. Kushak’s results suggested that microbial changes in the large intestine could have a greater impact on the pathology of ASD than the changes in the small intestine. Therefore, a better representation of the microbial gut milieu could be achieved by collecting mucosal samples from all over the GI tract for comparison of the microbiota resulting in a better understanding of the inter-relationships of the microbiota functioning and the interaction with the host. </p>
<p>Biopsies from the ileum and the caecum of fifteen ASD children (seven controls) showed a lower abundance of Bacteroides leading to a significantly higher Firmicutes to Bacteroidetes ratio [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. Levels of Clostridiales (Firmicutes) were slightly elevated in ASD group, especially the families Lachnospiraceae and Ruminococcaceae and the genus <italic>Faecalibacterium</italic>. The class Betaproteobacteria (Proteobacteria) was significantly higher abundant in faecal samples of the caecum in ASD patients, within the class Betaproteobacteria the family Alcaligenaceae was the highest abundant [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. Concomitant with increasing levels of Bacteroidetes the mRNA levels of SGLT1 in ileum and caecum significantly increased, whereas the mRNA levels of sucrase isomaltase (disaccharidase) decreased in the caecum. With increasing mRNA levels of sucrose isomaltase a significant decreased amount of Firmicutes was observed in the caecum [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. These associations may be of therapeutic interest, as they demonstrated how bacterial composition influenced expressions of the host’s sugar transporters and enzymes to consequently alter their nutrients’ availability. Therefore, directing the bioactive therapeutic molecules to the small intestine or the colon may be a practical approach to circumvent systematic absorption achieving a specific modulation of the microbiota in these organs.</p>
<p>Sibling control studies delivered discordant results. A Slovakian study enrolling twenty-nine participants including autistic children, their siblings and healthy children found that the amount of <italic>Lactobacillus</italic> spp was significantly increased (<xref ref-type="fig" rid="ijms-20-02115-f003">Figure 3</xref>) in the faeces of autistic children compared to siblings and healthy controls. Amount of <italic>Desulfovibrio</italic> and <italic>Clostridia</italic> spp were also increased, whereas <italic>Bifidobacterium</italic> spp were decreased in autistic children (<xref ref-type="fig" rid="ijms-20-02115-f003">Figure 3</xref>) [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]. The authors associated the severity of behavioural symptoms in social interaction, communication and restricted/repetitive behaviour in ASD with the amount of <italic>Desulfovibrio</italic> spp present. Therefore, <italic>Desulfovibrio</italic> spp were considered pathogenic microbes. Interestingly, non-autistic siblings of autistic children showed lower abundance of Bacteroidetes and higher abundance of Firmicutes compared to healthy controls with no family history of ASD [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]. Furthermore, non-autistic siblings had lower abundance of <italic>Clostridia</italic> and <italic>Desulfovibrio</italic> spp and significantly lower counts of <italic>Bifidobacterium</italic> spp compared to autistic children. Therefore, it was postulated that the levels of bacterial spp could be the tipping factor between autistic or healthy phenotypes [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]. In contrast, Gondalia et al. found no significant difference in microbial composition after analysing fifty-one autistic children and their fifty-three non-autistic siblings [<xref ref-type="bibr" rid="B91-ijms-20-02115">91</xref>]. Similarly, a different study including fifty-nine autistic children and forty-four non-autistic siblings also found no significant difference in the composition of the gut microbiota [<xref ref-type="bibr" rid="B92-ijms-20-02115">92</xref>]. These data suggest that the microbiota of siblings are similar and independent from their autistic phenotype [<xref ref-type="bibr" rid="B91-ijms-20-02115">91</xref>], probably as a result of the shared environment and genetic makeup [<xref ref-type="bibr" rid="B93-ijms-20-02115">93</xref>]. </p>
<p>Higher occurrence of <italic>Clostridium</italic> spp in the gut was associated with disease severity using the Childhood Autism Rating score (CARs score) [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>]. Significantly higher counts of the bacterium <italic>Clostridium perfringens</italic> were found in faecal samples of thirty-three autistic children compared to thirteen controls. Especially the spp <italic>Clostridium perfringens</italic> producing the beta2-toxin gene was significantly elevated in autistic children. The authors also found a significant relationship between the abundance of the beta2-toxin gene and occurrence of ASD [<xref ref-type="bibr" rid="B21-ijms-20-02115">21</xref>]. Herbicides were considered to preserve <italic>Clostridia</italic> spp and harm beneficial bacteria [<xref ref-type="bibr" rid="B94-ijms-20-02115">94</xref>]. A review suggested that a sub-acute tetanus infection with a <italic>Clostridium</italic> spp might be the cause of some cases of ASD. Infection with the pathogen <italic>Clostridium tetani</italic> only occurs in dysbiotic GI tracts, as it is an opportunistic pathogen. It may be inactive for several months until favourable conditions allow its growth. <italic>Clostridium tetani</italic> produces tetanus neurotoxin, which crosses the intestinal barrier. Tetanus neurotoxin is then transported via the vagal nerve to the nucleus solitarius and subsequently to the whole CNS. Tetanus neurotoxin inhibits the release of synaptic vesicles containing neurotransmitters by irreversibly cleaving synaptobrevin, a membrane-associated protein, which is important for vesicle stability. Synapses with cleaved synaptobrevin degenerate and lower synaptic activity correlates with diminished social behaviour found in ASD (<xref ref-type="fig" rid="ijms-20-02115-f004">Figure 4</xref>). Tetanus neurotoxin targets inhibitory neurons releasing GABA or glycine. Purkinje and granular cells in the cerebellum express receptors for the neurotoxin and the purkinje cells release GABA as neurotransmitter, making them vulnerable to the toxin. This is in line with the observation of decreased Purkinje and granular cells in autopsies of autistic children [<xref ref-type="bibr" rid="B43-ijms-20-02115">43</xref>].</p>
<p>The yeast Candida appears to play a role in autistic children as well. Strati et al. found significantly elevated abundances of the bacterial genera <italic>Collinsella</italic>, <italic>Corynebacterium</italic>, <italic>Dorea</italic> and <italic>Lactobacillus</italic> in the faeces of forty autistic children when compared to healthy children. Lowered levels of <italic>Alistipes</italic>, <italic>Bilophila</italic>, <italic>Dialister</italic>, <italic>Parabacteroides</italic> and <italic>Veillonella</italic> were also found in autistic children. Additionally, the authors found the yeast <italic>Candida</italic> to be present at increased rates in autistic children. Constipation could be associated with higher levels of <italic>Escherichia</italic>, <italic>Shigella</italic> and <italic>Clostridium</italic> cluster XVIII and lower levels of <italic>Gemmiger</italic> and <italic>Ruminococcus</italic> [<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. <italic>Lactobacillus</italic> spp stimulate the immune system to produce IL-22. IL-17 and IL-22 together inhibited the overgrowth of <italic>Candida</italic> spp, however in autistic population, the altered diversity of microbial community favoured the growth of <italic>Candida</italic> spp. Furthermore, <italic>Candida</italic> spp, once established in the gut, prevented recolonization of commensal microbes [<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. Several studies found notably higher abundance of <italic>Candida</italic> spp, especially <italic>Candida albicans</italic> in the faecal samples of autistic children compared to healthy counterparts [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>,<xref ref-type="bibr" rid="B95-ijms-20-02115">95</xref>]. Kantarcioglu et al. investigated the abundance of <italic>Candida</italic> spp in the gut of 415 autistic children (and 403 controls), which was elevated. Reportedly this yeast is associated with some autistic behaviour and 60 % of the healthy population is estimated to be asymptomatic carrier of <italic>Candida</italic> spp [<xref ref-type="bibr" rid="B95-ijms-20-02115">95</xref>]. Normally, <italic>Candida</italic> cannot grow in the healthy microbial environment due to the competition for space and nutrients and suppression by commensal bacteria. However, in a dysbiotic environment as frequently observed in the autistic population, the yeast proliferates and produces ammonia and toxins, which were reported to increase autistic behaviour [<xref ref-type="bibr" rid="B95-ijms-20-02115">95</xref>]. <italic>Candida</italic> spp also cause malabsorption of minerals and carbohydrates potentially playing a role in the ASD pathophysiology. </p>
<p>A simulation by Weston et al. showed the interdependency between the anti-inflammatory genera <italic>Bifidobacterium</italic> and the pro-inflammatory <italic>Clostridia</italic> and <italic>Desulfovibrio</italic>. <italic>Bifidobacterium</italic> is inhibited by lysozyme and the growth of <italic>Desulfovibrio</italic>. To some extent, <italic>Desulfovibrio</italic> thrives on metabolites produced by <italic>Bifidobacterium</italic>. Growth of <italic>Clostridia</italic> is inhibited by lysozymes and by a higher abundance of <italic>Bifidobacterium</italic>. The authors claimed that the growth of <italic>Clostridia</italic> in the gut with low abundances of Bifidobacterium is a key risk for the development of ASD [<xref ref-type="bibr" rid="B96-ijms-20-02115">96</xref>]. Another simulated study analysed the microbiome coding for enzymes involved in the metabolism of glutamate and found that these enzymes were underrepresented in autistic microbiome compared to healthy ones. Glutamate is a constituent of the important peptide glutathione, which is an antioxidant and therefore reduces oxidative stress in the cell. This amino acid is also an excitatory neurotransmitter. An imbalance in the CNS between excitation and inhibition has been postulated to contribute to ASD [<xref ref-type="bibr" rid="B97-ijms-20-02115">97</xref>]. A general observed trend is that <italic>Bifidobacterium</italic> spp are scarcer represented in the guts of autistic children, whereas <italic>Clostridia</italic> spp are higher abundant [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>].</p>
<p>Detecting altered microbial composition is especially important to understand how microbial metabolites can modulate gut and neuronal functions. Future studies are needed to establish a possible causation. Nevertheless, a significantly changed microbial composition was found in the GI tracts of autistic population pointing to a correlation between the microbiota and the occurrence of ASD. However, some of the mentioned results contradict each other. Conflicting results have been found for example for Oscillospira spp [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B89-ijms-20-02115">89</xref>], Collinsella spp [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>] and Parabacteroides spp [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. Therefore, conclusive evidence is yet to be established by future studies.</p>
</sec>
<sec id="sec5dot2-ijms-20-02115">
<title>5.2. Altered Concentrations of Metabolites and Their Functional Consequences</title>
<sec id="sec5dot2dot1-ijms-20-02115">
<title>5.2.1. Urinary Analysis</title>
<p>A study by Xiong et al. analysed urinary samples from sixty-two autistic and sixty-two non-autistic controls. They found significantly higher concentrations of 3-(3-hydroxyphenyl)- 3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid in samples of autistic children (<xref ref-type="table" rid="ijms-20-02115-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]. These data are in line with the proposition that 3-(3-hydroxyphenyl)-3-hydroxypropionic acid induce autistic symptoms by decreasing catecholamine levels in the brain [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>]. After oral administration of Vancomycin and supplementation of the probiotic <italic>Bifidobacterium</italic> to these children the mentioned metabolites significantly decreased [<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]. Vancomycin is an antibiotic, which is poorly absorbed by the GI mucosa and has a great effect on gram-positive bacteria such as <italic>Clostridia</italic> spp. The decrease of 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid after treatment suggests that these metabolites are mostly produced by <italic>Clostridia</italic> spp and other overgrown populations in an altered phenylalanine metabolism. The treatment showed improved eye contact behaviour and less constipation in autistic children [<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]. This finding was in line with the observation that children with altered phenylalanine metabolism, such as phenylketonuria, also often develop ASD [<xref ref-type="bibr" rid="B100-ijms-20-02115">100</xref>].</p>
<p>Some Clostridiaceae spp are known to produce metabolites such as phenols, <italic>p</italic>-cresol and indoles, all of which may act as toxins on the human metabolism [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. <italic>P</italic>-cresol, which was investigated as a possible biomarker for ASD, was elevated in the urinary [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>,<xref ref-type="bibr" rid="B102-ijms-20-02115">102</xref>] and faecal [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>] samples of autistic children (<xref ref-type="table" rid="ijms-20-02115-t001">Table 1</xref>). <italic>P</italic>-cresol has an inhibitory effect on the enzyme dopamine-beta-hydroxylase and thereby regulates the metabolism of the important neurotransmitter dopamine in the brain [<xref ref-type="bibr" rid="B100-ijms-20-02115">100</xref>]. As <italic>p</italic>-cresol is only produced in the GI tract, its occurrence in the system correlated with increased permeability of the gut. In addition, <italic>p</italic>-cresol was shown to correlate with autistic behaviour and the severity of the disease [<xref ref-type="bibr" rid="B103-ijms-20-02115">103</xref>].</p>
<p>Yap et al. compared urinary metabolite profiles of thirty-nine autistic children, twenty-eight non-autistic siblings and thirty-four healthy controls using NMR spectroscopy. Autistic children were found to excrete significantly more <italic>N</italic>-methyl-2-pyridone-5-carboxamide, <italic>N</italic>-methyl nicotinic acid, and <italic>N</italic>-methyl nicotinamide in their urine. Knowing that nicotinamide derives from tryptophan, this finding suggested ASD-associated alterations of the nicotinamide and the tryptophan metabolism [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. Other significantly elevated metabolites in the urinary profile of ASD children were acetate, dimethylamine, <italic>N</italic>-acetyl glycoprotein fragments, succinate and taurine. Significantly lower levels of glutamate, hippurate and phenylacetylglutamine were present in the urinary profile of ASD children. Precursors of phenylacetylglutamine and hippurate are phenylacetic acid and benzoic acid, which are both produced by bacterial metabolism [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. Hippurate is benzoic acid conjugated with glycine [<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]. <italic>N</italic>-methyl-2-pyridone-5-carboxamide, <italic>N</italic>-methyl nicotinic acid, and <italic>N</italic>-methyl nicotinamide are end products of the nicotinamide pathway. It is worth mentioning that no major differences in the metabolic profile was observed comparing healthy siblings to autistic children or non-autistic controls. This indicated that siblings of autistic children exhibited a metabolic profile in between their autistic siblings and normal controls [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. </p>
<p>In their urinary metabolite profile of thirty autistic children Gevi et al. found major differences in the tryptophan and purine metabolism compared to thirty non-autistic children. Other significantly perturbed pathways were the vitamin B6 pathway and the phenylalanine- tyrosine-tryptophan biosynthesis, among others [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]. Additionally, increased levels of tryptophan degradation products were found in the urine suggesting increased production of tryptophan or increased abnormal degradation [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>]. Several pathways utilize tryptophan in the human body (<xref ref-type="fig" rid="ijms-20-02115-f005">Figure 5</xref>). Indican or indolyl-lactate is produced by bacterial degradation. Through the human metabolism in the kynurenine pathway, kynurenic acid, xanthurenic acid or quinolinic acid are generated. Serotonin and melatonin are produced in another pathway from tryptophan (<xref ref-type="fig" rid="ijms-20-02115-f005">Figure 5</xref>). In the autistic metabolome kynurenic acid and melatonin are found in much lower concentration and xanthurenic acid and quinolinic acid are elevated compared to controls. The enzyme kynureninase uses vitamin B6 as cofactor. Therefore, B6 deficiency explains lower concentrations of kynurenic acid and elevated levels of xanthurenic acid and quinolinic acid in the kynurenine pathway [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]. Also, greater amounts of indolyl-3-acetic acid and indolyl-lactate were found in the urine [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>] and indole and 3-methylindole in the faeces of autistic children [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Following species produce indoles: <italic>Escherichia coli</italic>, <italic>Proteus vulgaris</italic>, <italic>Paracolobactrum coliform</italic>, <italic>Achromobacter liguefaciens</italic>, <italic>Bacteroides</italic> spp [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>] and <italic>Clostridium</italic> spp [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Indole is absorbed in the gut, thereafter it is oxidized and sulphated in the liver to indoxyl sulphate. Indoxyl sulphate may lead to an accumulation of several neurotransmitters in the brain, blocking the efflux transporter in the BBB [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]. A study revealed increased excretion of sulphate, sulphite and thiosulphate into the urine in ASD. They reasoned that this finding was due to dysfunctional sulphate transporters in the renal tube cells, hindering the reabsorption of these metabolites [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>].</p>
<p>Other metabolites found in altered concentrations were TNF-α, free amino acids and quorum sensing molecules (<xref ref-type="table" rid="ijms-20-02115-t001">Table 1</xref>). TNF-α was found in heightened levels in the faeces of autistic children, which correlated with the severity of GI symptoms [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]. Because increased TNF-α and IL-6 can also be a marker of inflammation in the brain [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>], these data re-confirmed a higher level of inflammation in the brains of autistic children. Circulating free amino acid levels were elevated in patients with ASD. Glutamate especially was found in higher quantities in the faeces of autistic patients. Glutamate is a neurotransmitter and the excess of it and can lead to apoptosis of neurons [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Quorum sensing molecules such as PhrCACET1 are signal molecules exchanged between bacteria. Several <italic>Clostridium</italic> spp synthesize PhrCACET1, which can readily cross the BBB. <italic>Clostridium</italic> spp are highly abundant in autistic individuals, therefore, the effect of PhrCACET1 should be closer investigated [<xref ref-type="bibr" rid="B107-ijms-20-02115">107</xref>].</p>
<p>Accumulatively, these data showed several altered metabolites in the urinary profile of autistic children, some even with correlation to autistic behaviour such as <italic>p</italic>-cresol. The metabolic pathways of tryptophan, purine, vitamin B6 and phenylalanine seem to be perturbed in ASD. Combination therapy with Vancomycin and <italic>Bifidobacterium</italic> led to amelioration of autistic symptoms such as improved eye contact and communication behaviour, assessed by the “Autism Behaviour Checklist” [<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]. In addition, the above therapy resulted in normalized levels of the metabolites 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid in the urine of autistic individuals [<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>] providing the existence of a possible link between these metabolites and the pathology of ASD. These metabolites indicated an altered phenylalanine metabolism in ASD. Further studies are warranted to work out the true potential of these metabolites as possible biomarkers for ASD. </p>
</sec>
<sec id="sec5dot2dot2-ijms-20-02115">
<title>5.2.2. Blood Analysis</title>
<p>Elevated levels of several soluble factors including neurotransmitter were observed in the blood of autistic patients. Serotonin levels in the whole blood were elevated in 23 % of the autistic children (<xref ref-type="table" rid="ijms-20-02115-t002">Table 2</xref>) [<xref ref-type="bibr" rid="B108-ijms-20-02115">108</xref>]. In addition, co-occurring GI symptoms were observed in children with ASD and children with hyperserotonaemia. However, the relationship between hyperserotonaemia and constipation was not unequivocal in the study [<xref ref-type="bibr" rid="B108-ijms-20-02115">108</xref>]. Serotonin serves as a major neurotransmitter in the CNS and the gut. In the GI tract, serotonin controls motility, pain perception and GI secretion. In the brain serotonin is responsible for regulating mood and cognition. In germ-free mice, higher levels of serotonin were found in the hippocampus and higher levels of tryptophan, the precursor of serotonin, in the blood [<xref ref-type="bibr" rid="B73-ijms-20-02115">73</xref>]. Known producers of serotonin are species from <italic>Candida</italic>, <italic>Streptococcus</italic>, <italic>Escherichia</italic> and <italic>Enterococcus</italic> [<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>]. Another neurotransmitter found in elevated concentration in autistic children was the inhibitory neurotransmitter GABA [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]. Some <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> spp are known producers of GABA [<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>,<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>,<xref ref-type="bibr" rid="B109-ijms-20-02115">109</xref>]. Producers of another neurotransmitter, noradrenaline, are spp from <italic>Bacillus</italic>, <italic>Enterococcus</italic>, <italic>Escherichia</italic>, <italic>Saccharomyces</italic> and <italic>Streptococcus</italic> [<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>,<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>]. Neurotransmitters produced in the gut act upon gut epithelial cells to produce active molecules that may reach and influence the CNS after the secretion into the periphery or by activating afferent neurons.</p>
<p>Autistic children are also known to have significantly lower plasma concentrations of glutathione, homocysteine, methionine and <italic>S</italic>-adenosylmethionine (<xref ref-type="table" rid="ijms-20-02115-t002">Table 2</xref>) [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. <italic>S</italic>-adenosylmethionine acts as an important methyldonor in the body and homocysteine is a precursor of <italic>S</italic>-adenosylmethionine, suggesting perturbations in the sulphur metabolism. Methylation and glutathione are used to lower oxidative stress in the cell. The methylation of nicotinic acid to <italic>N</italic>-methyl-2-pyridone-5-carboxamide, <italic>N</italic>-methyl nicotinic acid, and <italic>N</italic>-methyl nicotinamide consumes even more methyl-donor leading to increased sensitivity to oxidative stress in cells of autistic children [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. The excretion of heavy metals is difficult in ASD patients due to the fact that glutathione is less available and transmethylation/transsulphuration pathways are altered [<xref ref-type="bibr" rid="B86-ijms-20-02115">86</xref>]. Acetaminophen (Paracetamol) is mal-tolerated by autistic individuals. Mal-toleration occurs also due to insufficient capability to sulphate and thus detoxify the drug and due to the abundance of higher levels of <italic>p</italic>-cresol in autistic children. This is in total agreement with the fact that non-autistic people with high <italic>p</italic>-cresol blood levels are also known to be intolerant to Paracetamol [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]. The above data indicates an alteration in the sulphur metabolism and a reduced reduction capability in the cells of autistic people owing to the decreased levels S-adenosylmethionine and its precursor homocysteine.</p>
<p>Examining metabolites in serum and in red blood cells in eleven Canadian autistic children revealed significantly lower concentrations of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (ARA) and lower ratio of omega-3 to omega-6 fatty acids in red blood cells compared to fifteen controls (<xref ref-type="table" rid="ijms-20-02115-t002">Table 2</xref>). Also, significantly lower concentrations of DHA, ARA and linoleic acid were found in the serum [<xref ref-type="bibr" rid="B110-ijms-20-02115">110</xref>]. Decreased fatty acids levels in patients might be a direct result of the eating pattern observed in autistic individuals and not a cause leading to autism. As constituents of neuronal membranes, both DHA and ARA play a role in the maturation of neuronal networks. DHA is also important for the myelination of axons [<xref ref-type="bibr" rid="B111-ijms-20-02115">111</xref>]. Both fatty acids are also modulator of gene expression in the cell, which could also be a contributing epigenetic factor for ASD [<xref ref-type="bibr" rid="B110-ijms-20-02115">110</xref>]. In conclusion, the picky eating habit observed in autistic children might be a contributing factor to ASD. </p>
<p>Another metabolite with altered concentration in ASD patients was thiamine-pyrophosphate (TPP). The concentration in the plasma was significantly decreased compared to controls. However, precursor concentrations (thiamine and thiamine-monophosphate) were similar in both groups (<xref ref-type="table" rid="ijms-20-02115-t002">Table 2</xref>) [<xref ref-type="bibr" rid="B112-ijms-20-02115">112</xref>]. Lower concentration of TPP could result from an impaired excretion from producing cells into the blood or an impaired uptake from the gut lumen. Indeed, over 40% of the gut microbiota are known to produce TPP. TPP is a cofactor to many enzymes in the mitochondria, most importantly transketolase in the oxidative pentose-phosphate pathway [<xref ref-type="bibr" rid="B112-ijms-20-02115">112</xref>]. A decreased function of transketolase leads to an accumulation of the substrate for the oxidative pathway, which in turn inhibits the reductive pathway of pentose-phosphate-pathway resulting in lower concentration of NADPH. Lower abundance of NADPH leads to an increased oxidative stress in the cell [<xref ref-type="bibr" rid="B112-ijms-20-02115">112</xref>]. Thus, decreased levels of TPP lead to a lessened reduction capacity, as they are a cofactor of transketolase inhibiting the production of NADPH. In summary, the reduced anti-oxidative capacity may lead to a cellular damage and a reduction of mitochondria’s capacity to produce energy in ASD individuals. Increased amounts of LPS were also found in the blood of autistic individuals (<xref ref-type="table" rid="ijms-20-02115-t002">Table 2</xref>) [<xref ref-type="bibr" rid="B56-ijms-20-02115">56</xref>,<xref ref-type="bibr" rid="B113-ijms-20-02115">113</xref>]. LPS is produced by gram-negative bacteria and exerts pro-inflammatory activity. Leakage through the BBB can cause inflammation in the brain through activating microglia. Heightened LPS levels in autistic individuals correlated with elevated IL-6 levels, another pro-inflammatory cytokine. An inflammation further compromises the integrity of the BBB, facilitating the accumulation of heavy metals in the brain tissue, including the cerebellum [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>,<xref ref-type="bibr" rid="B56-ijms-20-02115">56</xref>], thus worsening the symptoms. </p>
</sec>
<sec id="sec5dot2dot3-ijms-20-02115">
<title>5.2.3. Short Chain Fatty Acids</title>
<p>SCFAs, mainly butyrate, propionate and acetate [<xref ref-type="bibr" rid="B114-ijms-20-02115">114</xref>], are produced as fermentation products by gut bacteria [<xref ref-type="bibr" rid="B115-ijms-20-02115">115</xref>,<xref ref-type="bibr" rid="B116-ijms-20-02115">116</xref>]. Lower concentrations of the total amount of SCFAs are found in autistic children [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>], providing the evidence for a reduced fermentation capacity of the microbiota. Nevertheless, propionate and acetate are found in higher levels in autistic children suggesting that butyrate production is dramatically reduced [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. SCFAs cross the BBB and influence early brain development by modulating production of the neurotransmitter serotonin and dopamine [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. These acids bind to two free fatty acid receptors (FFA2 and FFA3) found in several areas of the brain [<xref ref-type="bibr" rid="B6-ijms-20-02115">6</xref>,<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>,<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]. The resorption of water and electrolytes in the colon is also to some degree regulated by SCFAs [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. They also modulate the cytokine production by T-cells [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. Positively correlated with total amount of SCFA were <italic>Faecalibacterium</italic>, <italic>Ruminococcus</italic> and <italic>Bifidobacterium</italic> genera, while the amount of <italic>Bacteroides</italic> spp was correlated with propionic acid in autistic individuals [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. <italic>Bacteroides</italic> spp, <italic>Porphyromonadaceae</italic> and <italic>Parabacteroides</italic> were positively correlated with the amount of propionate and butyrate in autistic individuals. Alcaligenaceae is also positively correlated with propionate, whereas the Bacteroidaceae is negatively correlated with acetate and total amount of SCFA in autistic children [<xref ref-type="bibr" rid="B118-ijms-20-02115">118</xref>]. </p>
<p>Intraventricular injection of propionate into rat pups caused behavioural and physiological changes as observed in ASD [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]. An accumulation of propionic acid can lead to prolonged neurodevelopment and seizures [<xref ref-type="bibr" rid="B16-ijms-20-02115">16</xref>]. <italic>Clostridia</italic> spp are known to produce exotoxins and propionate and thus create an inflammatory status, which might worsen autistic symptoms [<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. As mentioned before, presence of an oxidative milieu in the cell, as seen in autistic individuals, leads among others to malfunctioning of mitochondrial enzymes and the production of reactive nitrogen species [<xref ref-type="bibr" rid="B119-ijms-20-02115">119</xref>]. The reactive nitrogen species interact with propionic acid and produce 3-nitropropionic acid. This acid acts as a mitochondrial neurotoxin, which irreversibly inhibits the function of the enzyme succinate dehydrogenase, which is implicated in the synthesis of NADH. Propionic acid is also converted to propionyl-CoA and enters the citric acid cycle at the enzyme succinyl-CoA-dehydrogenase. Two enzymes which are important to produce NADH are surpassed by 3-nitropropionic acid [<xref ref-type="bibr" rid="B119-ijms-20-02115">119</xref>]. NADH is a substrate for the electron transport chain and consequently for ATP production. This explains the lower activity of ETC enzyme complex I due to reduced substrate concentration [<xref ref-type="bibr" rid="B119-ijms-20-02115">119</xref>]. Propionate is involved in up-regulating the cyclic-adenosine-monophosphate response element binding protein (CREB). CREB regulates synaptic plasticity, memory formation and the reward system [<xref ref-type="bibr" rid="B120-ijms-20-02115">120</xref>]. A study by Frye et al. compared mitochondrial function of lymphoblastoid cells from autistic subjects and controls after incubating them in propionic acid and introduction to reactive oxygen species (ROS). Propionic acid metabolised by healthy lymphoblastoid cells exerted beneficial effects on the cells such as increased respiration. Cells from autistic individuals consumed propionic acid much faster as a fuel, suggesting a compensatory measurement for energy production. The consequence of the stronger reaction to ROS after propionic acid incubation by lymphoblastoid cells of autistic subjects was, among others, an increased proton leakage from the mitochondria to the inter-membrane space and hence a reduced respiratory capacity [<xref ref-type="bibr" rid="B119-ijms-20-02115">119</xref>].</p>
<p>Butyrate is used as an energy source in colonocytes [<xref ref-type="bibr" rid="B62-ijms-20-02115">62</xref>]. It is involved in regulating inflammatory and oxidative state of the mucosal cells, visceral sensitivity and motility and reinforces the mucosal barrier in the intestines. It prevents carcinogenesis and inflammation in the gut via its anti-inflammatory properties [<xref ref-type="bibr" rid="B114-ijms-20-02115">114</xref>]. Butyrate modulates the biosynthesis of catecholamines and neurotransmitters in the CNS and autonomic nervous system [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>]. Butyrate is said to be the most important SCFA in humans as it exhibits neuroprotective features. It promotes memory formation and neuronal plasticity through epigenetic modulation [<xref ref-type="bibr" rid="B121-ijms-20-02115">121</xref>]. In some neurodegenerative models butyrate was found to ameliorate symptoms [<xref ref-type="bibr" rid="B121-ijms-20-02115">121</xref>]. Even if not conclusive, the above data suggest an involvement of increased acetate and propionate and decreased butyrate in the pathophysiology of ASD.</p>
</sec>
</sec>
<sec id="sec5dot3-ijms-20-02115">
<title>5.3. Other Etiologies for ASD</title>
<p>Over one hundred genes are associated with the pathology of ASD and up to several hundred genes are implicated in elevation of the susceptibility to ASD [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>]. Most of the affected genes are implicated in synapse plasticity [<xref ref-type="bibr" rid="B122-ijms-20-02115">122</xref>] and brain development in utero as well as during infancy [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. Most of the differing gene expression lead to an altered structure of the CNS or the enteric nervous system [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>]. ASD has been hypothesised to be linked to abnormalities of the neural crest development during pregnancy [<xref ref-type="bibr" rid="B123-ijms-20-02115">123</xref>]. Inoue et al. found in peripheral blood mononuclear cells of autistic children, 1056 up-regulated and 517 down-regulated genes, respectively [<xref ref-type="bibr" rid="B124-ijms-20-02115">124</xref>]. Comorbidities such as fragile X syndrome, tuberous sclerosis or Rett disorder have also been observed in ASD patients (<xref ref-type="fig" rid="ijms-20-02115-f002">Figure 2</xref>) [<xref ref-type="bibr" rid="B27-ijms-20-02115">27</xref>]. Six Japanese autistic children were compared to six healthy controls regarding microbial composition by collecting faeces and blood. The genus <italic>Faecalibacterium</italic> was higher and <italic>Blautia</italic> lower represented in the faeces of autistic children [<xref ref-type="bibr" rid="B124-ijms-20-02115">124</xref>]. Moreover, there were several up- and down regulated genes in autistic children compared to healthy ones. Interestingly some genes, which are involved in IFN-gamma mediated pathways correlated with the differing abundances of <italic>Faecalibacterium</italic> and <italic>Blautia</italic> [<xref ref-type="bibr" rid="B124-ijms-20-02115">124</xref>]. These data are in accord with the finding that IFN-gamma is elevated in autistic children, which suggests a chronic inflammation in these children.</p>
<p>Another aetiology for ASD-like behaviour in mice was the exposure to bisphenol A <italic>in utero</italic>. Bisphenol A changed the DNA methylation and thus, the expression level of the gene for BDNF [<xref ref-type="bibr" rid="B125-ijms-20-02115">125</xref>]. BDNF is important for survival of neurons, growth and differentiation of newly formed neurons as well as new formations of synapses [<xref ref-type="bibr" rid="B72-ijms-20-02115">72</xref>]. </p>
<p>The data above indicates that several genes, which are involved in CNS development and inflammation pathways, are altered in autistic individuals providing several targets for a better understanding of the mechanisms involved in the disease and possible therapeutic targets. </p>
</sec>
</sec>
<sec id="sec6-ijms-20-02115">
<title>6. Possible Therapeutic Measures Acting on the Microbiota</title>
<sec id="sec6dot1-ijms-20-02115">
<title>6.1. Prebiotics</title>
<p>Dietary prebiotics were defined as “a selectively fermented ingredient that results in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host health” [<xref ref-type="bibr" rid="B77-ijms-20-02115">77</xref>,<xref ref-type="bibr" rid="B126-ijms-20-02115">126</xref>].</p>
<p>Grimaldi et al. investigated the role of the prebiotic galactooligosaccharide (GOS) in a synthetic colon model comparing diluted faecal samples from autistic children and controls regarding changes in bacterial composition and metabolic profile. The administration of the prebiotic led to significant increases in <italic>Bifidobacteria</italic> spp in both autistic and control models [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]. Slightly significant increases of the <italic>Clostridium</italic> cluster XI and decreases of Veillonellaeceae were observed only in the ASD group. Significant decreases occurred in <italic>Sutterella</italic> spp, <italic>Bacteroides</italic>, Clostridial cluster IX, <italic>Escherichia coli</italic>, Veillonellaceae, <italic>Ruminococcus</italic> spp, <italic>Clostridium leptum</italic> and <italic>Faecalibacterium prausnitzii</italic> in autistic children. Growth of <italic>Bifidobacteria</italic> could be stimulated by the prebiotic [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]. GOS also affected SCFA production, increasing butyrate and decreasing propionate. Thus, it is sensible to postulate that the effects of the GOS supplementation in these children were, at least partially, through the production of acetate and butyrate [<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]. </p>
<p>Prebiotics are not widely researched as a treatment option for autistic individuals. Nonetheless, existing data point to the fact that prebiotic treatment can cause microbial compositional alterations in autistic children that could result in amelioration of autistic symptoms. As mentioned before, methodologies to deliver therapeutics, such as specific SCFA or prebiotics, to the GI tract could be envisaged to directly target the colon to reach the microbiota without the interference of the digestive system.</p>
</sec>
<sec id="sec6dot2-ijms-20-02115">
<title>6.2. Probiotics</title>
<p>Probiotics contain living microorganisms and are administered to promote health by stimulating immunity, strengthening the intestinal barrier, increasing the expression of mucine, reducing the overgrowth of pathogens and producing vitamins and antioxidants [<xref ref-type="bibr" rid="B1-ijms-20-02115">1</xref>,<xref ref-type="bibr" rid="B127-ijms-20-02115">127</xref>]. The most commonly used probiotics are Bifidobacterium spp and Lactobacillus spp [<xref ref-type="bibr" rid="B56-ijms-20-02115">56</xref>]. </p>
<p>The administration of the probiotic cocktail “Children Dophilus”, containing strains from <italic>Lactobacillus</italic>, <italic>Bifidobacterium</italic> and <italic>Streptococcus</italic> [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>], three times a day for four months shifted the Bacteroidetes/Firmicutes ratio towards more Bacteroidetes (<xref ref-type="table" rid="ijms-20-02115-t003">Table 3</xref>). The abundances of the genera Desulfovibrio and Bifidobacterium also increased in autistic children. The administration of the probiotic mixture of <italic>Lactobacillus rhamnosus</italic>, <italic>Bifidobacterium infantis</italic>, <italic>Bifidobacterium longus</italic>, <italic>Lactobacillus helveticus</italic>, <italic>Lactobacillus reuteri</italic> and <italic>Lactobacillus paracasei</italic> to autistic children improved comorbid GI problems [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>]. <italic>Lactobacillus reuteri</italic> on its own could reverse intestinal inflammation caused by LPS [<xref ref-type="bibr" rid="B46-ijms-20-02115">46</xref>]. Furthermore, the bacterium <italic>Lactobacillus reuteri</italic> influenced the posterior pituitary gland to produce more oxytocin. Oxytocin is a hypothalamic hormone positively influencing social behaviour [<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>]. It remains to be determined whether increased levels of oxytocin in autistic children could ameliorate their behaviour in social interactions in a well-designed experimental setting.</p>
<p>The administration of <italic>Bifidobacterium</italic> spp to mice for 8 weeks resulted in higher concentration of ARA and DHA in their brains [<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]. This altered fatty acids composition in the brain exerted a beneficial effect on neurogenesis, neurotransmission and preventing oxidative stress. Learning and memory were also positively affected by these fatty acids [<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]. The administration of <italic>Lactobacillus rhamnosus</italic> in mice, on the other hand, reduced corticosterone levels and thereby positively influenced anxiety and depression. Another observed effect was altered levels of GABA and its receptors throughout the brain. These effects could only be achieved with an intact vagal nerve, a fact that reconfirms the role of the vagal nerve as a major route of communication between the brain and the gut microbiota [<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>].</p>
<p>Hsiao et al. treated gut permeability and altered microbial composition by oral administration of the commensal microbe <italic>Bacteroides fragilis</italic> in MIA mice showing improvements of autistic features as well as amelioration of deficits in anxiety-like behaviour. Interestingly the probiotic also corrected altered expression of the tight junction proteins CLDN-8 and CLDN-15 in the colon. Heightened levels of IL-6 found in the colon of MIA mice were normalised, which led to improved gut barrier function. A metabolite, which was found in significantly higher levels in the serum of MIA mice is 4-ethylphenylsulfate, which is chemically similar to <italic>p</italic>-cresol and is produced by <italic>Clostridia</italic> spp. The authors convincingly showed that the oral administration of <italic>Bacteroides fragilis</italic> corrected serum levels of 4-ethylphenylsulfate in MIA mice [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]. </p>
<p>Probiotics are known to alter the microbial composition in the gut of autistic children. The experimental evidence for the positive behavioural changes observed in MIA mice after administration of <italic>Bacteroides fragilis</italic> raise the interesting question whether the same result also applies to humans [<xref ref-type="bibr" rid="B128-ijms-20-02115">128</xref>].</p>
</sec>
<sec id="sec6dot3-ijms-20-02115">
<title>6.3. Faecal Microbiota Transplantation</title>
<p>In contrast to probiotic treatment, where just some bacterial strains are supplemented, faecal microbiota transplantation (FMT) ensures the transfer of several hundred bacterial strains. A healthy individual donates a stool sample [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>], which is normally used freshly within eight hours or within eight weeks when directly frozen after donation [<xref ref-type="bibr" rid="B129-ijms-20-02115">129</xref>]. FMT could potentially be problematic, as donors could transfer opportunistic pathogens or infections to recipients. A thorough screening of donors before donation minimises the risk but in the early stages of infections donors could be asymptomatic and unknowingly transfer infections [<xref ref-type="bibr" rid="B130-ijms-20-02115">130</xref>]. Despite these uncertainties, FMT is an established and efficient therapy in recurrent <italic>Clostridium difficile</italic> infection [<xref ref-type="bibr" rid="B77-ijms-20-02115">77</xref>,<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>,<xref ref-type="bibr" rid="B131-ijms-20-02115">131</xref>,<xref ref-type="bibr" rid="B132-ijms-20-02115">132</xref>].</p>
<p>Kang et al. studied the impact on the microbial composition and the course of GI and autistic symptoms in eighteen autistic children after “Microbiota Transfer Therapy” [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>]. The transfer followed over a period of 7–8 weeks after oral administration of Vancomycin and bowel cleansing. The results were impressing, because GI symptoms such as constipation, diarrhoea or abdominal pain decreased by 80%. The improvement lasted at least for eight weeks. This study showed clearly an improvement of not only GI but also seventeen ASD behavioural symptoms assessed by the “Parental Global Impressions-III” after FMT [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>]. The main consequence of faecal transplantation was an increased bacterial diversity and altered abundances of some bacteria such as the genera <italic>Bifidobacterium</italic>, <italic>Prevotella</italic> and <italic>Desulfovibrio</italic>. This suggests that GI and behavioural symptoms in autistic children are inter-connected and trace back to lesser microbial diversity probably through modulating metabolites [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>].</p>
<p>Therefore, FMT is an exciting new treatment option, which could be considered for ASD patients with dysbiosis.</p>
</sec>
<sec id="sec6dot4-ijms-20-02115">
<title>6.4. Other Treatment Strategies</title>
<p>Amelioration of behavioural symptoms could also be reached through oral treatment with Vancomycin, which is an antibiotic specific to bacteria such as Clostridiaceae [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. This finding suggests a connection between Clostridiaceae and autistic behaviour. However, the amelioration of the symptoms did not last longer than the treatment duration [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. This was attributed to the spore forming capacity of these bacteria as bacterial spores can survive antibiotic treatment and proliferate afterwards [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. Also, a restricted gluten and/or casein-free diet seemed to positively affect the social and cognitive problems in children with ASD [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. One hypothesis is that these food components are metabolised to opioid-like substances and act in the CNS [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>,<xref ref-type="bibr" rid="B133-ijms-20-02115">133</xref>]. However, the evidence is rather weak, as opioid-like substances were not found in autistic individuals. Therefore, the therapeutic value of omitting gluten and casein free diet is limited and should only be considered if there are allergic reactions to the abovementioned food components [<xref ref-type="bibr" rid="B86-ijms-20-02115">86</xref>,<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>].</p>
<p>Interestingly, higher rates of ASD have been reported in people with dark skin and in regions with limited solar irradiation. Significantly lower levels of 25-hydroxy-Vitamin D in serum were found in autistic children in comparison to controls. In a study vitamin D supplementation was given to rat pups to treat ASD induced by propionic acid. The authors discovered that vitamin D has neuroprotective features and less DNA breaks were detected in the brains of rats treated with vitamin D compared to untreated propionic acid induced rats. These results, however, could only be obtained, when the pups were treated with vitamin D before inducing autism. In conclusion, the study suggested that vitamin D exhibits rather a preventive than a therapeutic effect [<xref ref-type="bibr" rid="B134-ijms-20-02115">134</xref>]. The administration of vitamin B1 to autistic children was also suggested to ameliorate symptoms due to vitamin B1 producing bacteria Prevotella being found in lower abundances in autistic children [<xref ref-type="bibr" rid="B20-ijms-20-02115">20</xref>]. </p>
<p>One publication even suggested the introduction of helminths, which are parasitic worms, into the gut ecosystem to achieve a greater diversity. One argument was that before daily hygienic measures were introduced in our society, helminths were a normal part of the gut microbiota and the prevalence for ASD was smaller [<xref ref-type="bibr" rid="B123-ijms-20-02115">123</xref>]. This hypothesis was experimentally supported by the data that the exposure of the immune activated rats to helminths resulted in less anxious behaviour [<xref ref-type="bibr" rid="B123-ijms-20-02115">123</xref>], which is considered to be a symptom of ASD in rodents [<xref ref-type="bibr" rid="B102-ijms-20-02115">102</xref>]. Obviously, these treatment options were poorly documented and are not recommended as a treatment option for ASD patients before thorough investigations. </p>
</sec>
</sec>
<sec id="sec7-ijms-20-02115" sec-type="discussion">
<title>7. Discussion and Conclusions</title>
<p>It remains yet to be unequivocally determined whether dysbiosis is a factor causing ASD or if the disease is causing the microbial alterations. The mutual correlation between ASD and alterations in the microbiota, however, has been undoubtedly confirmed by many animal and human studies [<xref ref-type="bibr" rid="B124-ijms-20-02115">124</xref>]. To further narrow down the mechanisms of disease, studies with bigger sample sizes are required, since the works summarized in this review showed varying degrees of statistical significance and some results are based on small sample sizes. Our review also showed big variations of methodologies and outcome measures calling for standardisation of the treatment regimens to achieve higher statistical significance and a better comparison between the study results.</p>
<p>This review article demonstrated significant changes in microbial composition of autistic population. Often observed changes in ASD children were a generally decreased bacterial diversity compared to control populations and the significantly decreased Bacteroidetes to Firmicutes ratio [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>,<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>,<xref ref-type="bibr" rid="B76-ijms-20-02115">76</xref>,<xref ref-type="bibr" rid="B87-ijms-20-02115">87</xref>]. Elevated abundances of <italic>Clostridium</italic> spp in autistic individuals correlated with the severity of autistic behaviour [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>]. An evolutionary explanation as to why the microbiota modulate our behaviour is, the more social the host is, the more the microbes can spread through society [<xref ref-type="bibr" rid="B135-ijms-20-02115">135</xref>].</p>
<p>The discovery and understanding the connection between the microbiota and ASD is especially important to find new treatment options for this disease. Treatment of autistic behaviour based on microbial compositional alterations such as probiotics and faecal microbiota transfer showed promising results in GF-mice and autistic individuals [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>,<xref ref-type="bibr" rid="B46-ijms-20-02115">46</xref>,<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>,<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>,<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>,<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]. The administration of probiotics resulted in improvement of comorbid GI problems [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>] or stimulation of the production of oxytocin, positively influencing social behaviour [<xref ref-type="bibr" rid="B24-ijms-20-02115">24</xref>,<xref ref-type="bibr" rid="B136-ijms-20-02115">136</xref>]. Especially, faecal microbiota transfers significantly ameliorated ASD behavioural symptoms and GI problems in autistic children [<xref ref-type="bibr" rid="B79-ijms-20-02115">79</xref>]. For widespread use of these treatments more studies must be conducted to finetune treatment, mode of delivery, safety, its duration and doses. </p>
<p>We suggest that the reduced mRNA expressions of disaccharidases and hexose transporters in the gut epithelium may be responsible for some of the alteration in microbial composition of ASD patients [<xref ref-type="bibr" rid="B53-ijms-20-02115">53</xref>]. More mono- and disaccharides entering the colon favour some bacterial species over others and consequently lead to an altered metabolome in the gut affecting the host. Such alterations may result in different expression levels of tight junction proteins [<xref ref-type="bibr" rid="B55-ijms-20-02115">55</xref>] leading to comorbidities such as increased intestinal permeability [<xref ref-type="bibr" rid="B15-ijms-20-02115">15</xref>] and a reduced integrity of the BBB in ASD patients. As a result of these changes, bacterial metabolites can enter and influence the CNS.</p>
<p>Significantly lower plasma concentration of S-adenosylmethionine, glutathione [<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>] and thiamine-pyrophosphate [<xref ref-type="bibr" rid="B112-ijms-20-02115">112</xref>] in ASD provide the evidence for a perturbation in transmethylation processes in the body and diminished reduction capability of the cell. Increased oxidative stress in the cells leads to malfunctioning of mitochondrial enzymes and production of reactive nitrogen species, which can interact with propionic acid and produce a mitochondrial neurotoxin worsening the reduction capability [<xref ref-type="bibr" rid="B119-ijms-20-02115">119</xref>]. Lower concentrations of the total amount of SCFAs are found in ASD patients [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>,<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>] with higher levels of propionate and indicating that butyrate production is dramatically reduced [<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]. The altering concentrations of the bacterial metabolites butyrate and propionate are likely to play a role in the pathophysiology of autism. A new possible family of substances with link to ASD is suggested in our review including 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid. These metabolites were increased in the urinary profile of ASD patients linking ASD to an abnormal phenylalanine metabolism. As a consequence of treating ASD patients with an antibiotic and a probiotic, these metabolites decreased in the urine of autistic patients. Additionally, autistic behaviour was ameliorated in the patients due to this treatment [<xref ref-type="bibr" rid="B38-ijms-20-02115">38</xref>]. The evidence for the predictive value of the suggested biomarkers is based on one well conducted study only. Therefore, the effectiveness of these molecules for prediction of ASD need to be validated in independent human studies, to reconfirm the finding that these metabolites are part of an autistic-behaviour-causing metabolome. </p>
<p>In conclusion, the correlation between changes in distinct bacterial populations and several bacterial metabolites, and the behavioural changes related to ASD warrant further investigations into the microbiota-gut-brain-axis aiming at in-depth examination of mechanisms leading to the pathology of autism. We presented here several epidemiological, experimental human and in vivo studies for the involvement of different microbes in the ASD pathology such as <italic>Clostridia</italic> spp and highlighted the evidence for several metabolites to be considered as possible biomarkers for ASD. Additional independent research following standardised protocols, and enrolling well-diagnosed bigger cohorts are urgently needed to definitely discover the interdependencies, the sequence of events leading to ASD, and to suggest unequivocal biomarkers and effective therapeutic strategies.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to thank Joshua Dan Itsch Csucker, Nilujana Srikantha and David Wolfer for useful comments and the review of this paper. </p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, P.S. and M.H.M.; Methodology, P.S. and M.H.M.; Validation, M.H.M.; Formal Analysis, P.S. and M.H.M.; Investigation, P.S.; Resources, P.S.; Data Curation, P.S.; Writing-Original Draft Preparation, P.S.; Writing-Review &amp; Editing, P.S. and M.H.M.; Visualization, P.S.; Supervision, M.H.M.; Project Administration, M.H.M. and P.S.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest. </p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ASD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Autism Spectrum disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BBB</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Blood-brain-barrier</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">BDNF </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Brain derived neurotropic factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">CLDN</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Claudine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DNA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Deoxyribonucleic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ETC</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Electron transport chain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">FMT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Faecal Microbiota transplantation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GABA </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Gamma-amino-butyric acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GI </td>
<td align="left" colspan="1" rowspan="1" valign="middle">Gastrointestinal </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GLT2</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glucose transporter 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HPA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Hypothalamus-pituitary-adrenal</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MIA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Maternal immune activation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NADH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nicotineamide-adenine-dinucleotide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NADPH</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nicotineamide-adenine-dinukleotide-phosphate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">poly(I:C)</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Polyinosinic:polycytidylic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ROS</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Reactive oxygen species</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SCFAs</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Short chain fatty acids</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">SGLT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Sodium dependent glucose transporter 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">spp</td>
<td align="left" colspan="1" rowspan="1" valign="middle">species</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TPP</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Thiamine-pyrophosphate</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-02115">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santocchi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Guiducci</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fulceri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Billeci</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Buzzigoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Apicella</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Calderoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Muratori</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Gut to brain interaction in Autism Spectrum Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters</article-title>
<source/>BMC Psychiatry
          <year>2016</year>
<volume>16</volume>
<elocation-id>183</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12888-016-0887-5</pub-id>
<pub-id pub-id-type="pmid">27260271</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-02115">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redinbo</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>The microbiota, chemical symbiosis, and human disease</article-title>
<source/>J. Mol. Biol.
          <year>2014</year>
<volume>426</volume>
<fpage>3877</fpage>
<lpage>3891</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2014.09.011</pub-id>
<pub-id pub-id-type="pmid">25305474</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-02115">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viggiano</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ianiro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vanella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bibbo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Simeone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mele</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Gut barrier in health and disease: focus on childhood</article-title>
<source/>Eur. Rev. Med. Pharmacol. Sci.
          <year>2015</year>
<volume>19</volume>
<fpage>1077</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="pmid">25855935</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-02115">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gershon</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>The bowel and beyond: the enteric nervous system in neurological disorders</article-title>
<source/>Nat. Rev. Gastroenterol. Hepatol.
          <year>2016</year>
<volume>13</volume>
<fpage>517</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1038/nrgastro.2016.107</pub-id>
<pub-id pub-id-type="pmid">27435372</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-02115">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Hsien</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sharon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hyde</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>McCue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Codelli</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reisman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>J.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders</article-title>
<source/>Cell
          <year>2013</year>
<volume>155</volume>
<fpage>1451</fpage>
<lpage>1463</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2013.11.024</pub-id>
<pub-id pub-id-type="pmid">24315484</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-02115">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The Microbiome-Gut-Brain Axis in Health and Disease</article-title>
<source/>Gastroenterol. Clin. North. Am.
          <year>2017</year>
<volume>46</volume>
<fpage>77</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.gtc.2016.09.007</pub-id>
<pub-id pub-id-type="pmid">28164854</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-02115">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muszer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Noszczynska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kasperkiewicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skurnik</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Human Microbiome: When a Friend Becomes an Enemy</article-title>
<source/>Arch. Immunol Ther. Exp. (Warsz)
          <year>2015</year>
<volume>63</volume>
<fpage>287</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1007/s00005-015-0332-3</pub-id>
<pub-id pub-id-type="pmid">25682593</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-02115">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petra</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Panagiotidou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hatziagelaki</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Theoharides</surname>
<given-names>T.C.</given-names>
</name>
</person-group>
<article-title>Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation</article-title>
<source/>Clin. Ther.
          <year>2015</year>
<volume>37</volume>
<fpage>984</fpage>
<lpage>995</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinthera.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">26046241</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-02115">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quigley</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Basic Definitions and Concepts: Organization of the Gut Microbiome</article-title>
<source/>Gastroenterol. Clin. North. Am.
          <year>2017</year>
<volume>46</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.gtc.2016.09.002</pub-id>
<pub-id pub-id-type="pmid">28164844</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-02115">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichtman</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Sonnenburg</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Monitoring host responses to the gut microbiota</article-title>
<source/>ISME J.
          <year>2015</year>
<volume>9</volume>
<fpage>1908</fpage>
<lpage>1915</lpage>
<pub-id pub-id-type="doi">10.1038/ismej.2015.93</pub-id>
<pub-id pub-id-type="pmid">26057846</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-02115">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latalova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hajda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prasko</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Can gut microbes play a role in mental disorders and their treatment?</article-title>
<source/>Psychiatr. Danub.
          <year>2017</year>
<volume>29</volume>
<fpage>28</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.24869/psyd.2017.28</pub-id>
<pub-id pub-id-type="pmid">28291971</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-02115">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stilling</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Microbial genes, brain &amp; behaviour - epigenetic regulation of the gut-brain axis</article-title>
<source/>Genes Brain Behav.
          <year>2014</year>
<volume>13</volume>
<fpage>69</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1111/gbb.12109</pub-id>
<pub-id pub-id-type="pmid">24286462</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-02115">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marler</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>McDonnell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Beversdorf</surname>
<given-names>D.Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of Rigid-Compulsive Behavior with Functional Constipation in Autism Spectrum Disorder</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2017</year>
<volume>47</volume>
<fpage>1673</fpage>
<lpage>1681</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-017-3084-6</pub-id>
<pub-id pub-id-type="pmid">28289979</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-02115">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fulceri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santocchi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cena</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Del Bianco</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Narzisi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calderoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Muratori</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Gastrointestinal symptoms and behavioral problems in preschoolers with Autism Spectrum Disorder</article-title>
<source/>Dig. Liver Dis.
          <year>2016</year>
<volume>48</volume>
<fpage>248</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/j.dld.2015.11.026</pub-id>
<pub-id pub-id-type="pmid">26748423</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-02115">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iovene</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Bombace</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maresca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sapone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iardino</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Picardi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marotta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schiraldi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Siniscalco</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intestinal Dysbiosis and Yeast Isolation in Stool of Subjects with Autism Spectrum Disorders</article-title>
<source/>Mycopathologia
          <year>2017</year>
<volume>182</volume>
<fpage>349</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1007/s11046-016-0068-6</pub-id>
<pub-id pub-id-type="pmid">27655151</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-02115">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berding</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs</article-title>
<source/>Nutr. Rev.
          <year>2016</year>
<volume>74</volume>
<fpage>723</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="doi">10.1093/nutrit/nuw048</pub-id>
<pub-id pub-id-type="pmid">27864534</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-02115">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buie</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Potential Etiologic Factors of Microbiome Disruption in Autism</article-title>
<source/>Clin. Ther.
          <year>2015</year>
<volume>37</volume>
<fpage>976</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinthera.2015.04.001</pub-id>
<pub-id pub-id-type="pmid">26046240</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-02115">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reddy</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Saier</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Autism and our intestinal microbiota</article-title>
<source/>J. Mol. Microbiol. Biotechnol.
          <year>2015</year>
<volume>25</volume>
<fpage>51</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1159/000375303</pub-id>
<pub-id pub-id-type="pmid">25792275</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-02115">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakefield</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>The gut-brain axis in childhood developmental disorders</article-title>
<source/>J. Pediatr Gastroenterol Nutr.
          <year>2002</year>
<volume>34</volume>
<issue>Suppl. 1</issue>
<fpage>S14</fpage>
<lpage>S17</lpage>
<pub-id pub-id-type="doi">10.1097/00005176-200205001-00004</pub-id>
<pub-id pub-id-type="pmid">12082381</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-02115">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Ilhan</surname>
<given-names>Z.E.</given-names>
</name>
<name>
<surname>Wallstrom</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Labaer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Krajmalnik-Brown</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e68322</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0068322</pub-id>
<pub-id pub-id-type="pmid">23844187</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-02115">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finegold</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Summanen</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Komoriya</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Detection of Clostridium perfringens toxin genes in the gut microbiota of autistic children</article-title>
<source/>Anaerobe
          <year>2017</year>
<volume>45</volume>
<fpage>133</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.anaerobe.2017.02.008</pub-id>
<pub-id pub-id-type="pmid">28215985</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-02115">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeidán Chuliá</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Clostridium Bacteria and its Impact in Autism Research: Thinking “Outside The Box” of Neuroscience</article-title>
<source/>J. Commun. Disord. Deaf Stud. Hearing Aids
          <year>2013</year>
<volume>1</volume>
<fpage>101</fpage>
<pub-id pub-id-type="doi">10.4172/2375-4427.1000101</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-02115">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Abdolmaleky</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Microbiome, inflammation, epigenetic alterations, and mental diseases</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr Genet.
          <year>2017</year>
<volume>174</volume>
<fpage>651</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32567</pub-id>
<pub-id pub-id-type="pmid">28691768</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-02115">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration</article-title>
<source/>J. Physiol.
          <year>2017</year>
<volume>595</volume>
<fpage>489</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1113/JP273106</pub-id>
<pub-id pub-id-type="pmid">27641441</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-02115">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fung</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>E.Y.</given-names>
</name>
</person-group>
<article-title>Interactions between the microbiota, immune and nervous systems in health and disease</article-title>
<source/>Nat. Neurosci.
          <year>2017</year>
<volume>20</volume>
<fpage>145</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4476</pub-id>
<pub-id pub-id-type="pmid">28092661</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-02115">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diaz Heijtz</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fetal, neonatal, and infant microbiome: Perturbations and subsequent effects on brain development and behavior</article-title>
<source/>Semin. Fetal. Neonatal. Med.
          <year>2016</year>
<volume>21</volume>
<fpage>410</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1016/j.siny.2016.04.012</pub-id>
<pub-id pub-id-type="pmid">27255860</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-02115">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madore</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leyrolle</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lacabanne</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Benmamar-Badel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Joffre</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nadjar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laye</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Autism: Plausible Role of Maternal Inflammation, Dietary Omega 3, and Microbiota</article-title>
<source/>Neural Plast.
          <year>2016</year>
<volume>2016</volume>
<fpage>3597209</fpage>
<pub-id pub-id-type="doi">10.1155/2016/3597209</pub-id>
<pub-id pub-id-type="pmid">27840741</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-02115">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Principi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Gut microbiota and central nervous system development</article-title>
<source/>J. Infect.
          <year>2016</year>
<volume>73</volume>
<fpage>536</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2016.09.010</pub-id>
<pub-id pub-id-type="pmid">27725185</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-02115">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Gut-Brain Axis and Behavior</article-title>
<source/>Nestle Nutr. Inst. Workshop Ser.
          <year>2017</year>
<volume>88</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1159/000461732</pub-id>
<pub-id pub-id-type="pmid">28346923</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-02115">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.B.</given-names>
</name>
</person-group>
<article-title>Impacts of gut bacteria on human health and diseases</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>7493</fpage>
<lpage>7519</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16047493</pub-id>
<pub-id pub-id-type="pmid">25849657</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-02115">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schumann</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Stereological analysis of amygdala neuron number in autism</article-title>
<source/>J. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>7674</fpage>
<lpage>7679</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1285-06.2006</pub-id>
<pub-id pub-id-type="pmid">16855095</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-02115">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Theije</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Bavelaar</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Lopes da Silva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Korte</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Garssen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kraneveld</surname>
<given-names>A.D.</given-names>
</name>
</person-group>
<article-title>Food allergy and food-based therapies in neurodevelopmental disorders</article-title>
<source/>Pediatr. Allergy Immunol.
          <year>2014</year>
<volume>25</volume>
<fpage>218</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1111/pai.12149</pub-id>
<pub-id pub-id-type="pmid">24236934</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-02115">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Tillisch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Gut/brain axis and the microbiota</article-title>
<source/>J. Clin. Invest.
          <year>2015</year>
<volume>125</volume>
<fpage>926</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1172/JCI76304</pub-id>
<pub-id pub-id-type="pmid">25689247</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-02115">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vuong</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>E.Y.</given-names>
</name>
</person-group>
<article-title>The Microbiome and Host Behavior</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2017</year>
<volume>40</volume>
<fpage>21</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-neuro-072116-031347</pub-id>
<pub-id pub-id-type="pmid">28301775</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-02115">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Vieira-Silva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liston</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raes</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>How informative is the mouse for human gut microbiota research?</article-title>
<source/>Dis. Model. Mech.
          <year>2015</year>
<volume>8</volume>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.017400</pub-id>
<pub-id pub-id-type="pmid">25561744</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-02115">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Genetic architecture, epigenetic influence and environment exposure in the pathogenesis of Autism</article-title>
<source/>Sci. China Life Sci.
          <year>2015</year>
<volume>58</volume>
<fpage>958</fpage>
<lpage>967</lpage>
<pub-id pub-id-type="doi">10.1007/s11427-015-4941-1</pub-id>
<pub-id pub-id-type="pmid">26490976</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-02115">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bik</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>The Hoops, Hopes, and Hypes of Human Microbiome Research</article-title>
<source/>Yale J. Biol. Med.
          <year>2016</year>
<volume>89</volume>
<fpage>363</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="pmid">27698620</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-02115">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>The microbiota-gut-brain axis and its potential therapeutic role in autism spectrum disorder</article-title>
<source/>Neuroscience
          <year>2016</year>
<volume>324</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.03.013</pub-id>
<pub-id pub-id-type="pmid">26964681</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-02115">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>
<source/>PLoS Med.
          <year>2009</year>
<volume>6</volume>
<elocation-id>e1000097</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>
<pub-id pub-id-type="pmid">19621072</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-02115">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Angelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piccolo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vannini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Siragusa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Giacomo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serrazzanetti</surname>
<given-names>D.I.</given-names>
</name>
<name>
<surname>Cristofori</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guerzoni</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Gobbetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Francavilla</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e76993</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0076993</pub-id>
<pub-id pub-id-type="pmid">24130822</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-02115">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mezzelani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raggi</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Marabotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milanesi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Ochratoxin A as possible factor trigging autism and its male prevalence via epigenetic mechanism</article-title>
<source/>Nutr. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>43</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1179/1476830515Z.000000000186</pub-id>
<pub-id pub-id-type="pmid">25597866</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-02115">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushak</surname>
<given-names>R.I.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Intestinal microbiota, metabolome and gender dimorphism in autism spectrum disorders</article-title>
<source/>Res. Autism Spectr. Disord.
          <year>2018</year>
<volume>49</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.rasd.2018.01.009</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-02115">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolte</surname>
<given-names>E.R.</given-names>
</name>
</person-group>
<article-title>Autism and Clostridium tetani</article-title>
<source/>Med. Hypotheses
          <year>1998</year>
<volume>51</volume>
<fpage>133</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-9877(98)90107-4</pub-id>
<pub-id pub-id-type="pmid">9881820</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-02115">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baio</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wiggins</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Maenner</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kurzius-Spencer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zahorodny</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Robinson Rosenberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014</article-title>
<source/>MMWR Surveill Summ.
          <year>2018</year>
<volume>67</volume>
<fpage>1</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.15585/mmwr.ss6706a1</pub-id>
<pub-id pub-id-type="pmid">29701730</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-02115">
<label>45.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Association</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders (DSM-5<sup>®</sup>)
          <publisher-name>American Psychiatric Publishing</publisher-name>
<publisher-loc>Washington, DC, USA</publisher-loc>
<year>2013</year>
</element-citation>
</ref>
<ref id="B46-ijms-20-02115">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rhoads</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Can probiotics benefit children with autism spectrum disorders?</article-title>
<source/>World J. Gastroenterol.
          <year>2016</year>
<volume>22</volume>
<fpage>10093</fpage>
<lpage>10102</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v22.i46.10093</pub-id>
<pub-id pub-id-type="pmid">28028357</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-02115">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manchia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fanos</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Targeting aggression in severe mental illness: The predictive role of genetic, epigenetic, and metabolomic markers</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2017</year>
<volume>77</volume>
<fpage>32</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.03.024</pub-id>
<pub-id pub-id-type="pmid">28372995</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-02115">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Padua</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tillisch</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Altered brain-gut axis in autism: comorbidity or causative mechanisms?</article-title>
<source/>Bioessays
          <year>2014</year>
<volume>36</volume>
<fpage>933</fpage>
<lpage>939</lpage>
<pub-id pub-id-type="doi">10.1002/bies.201400075</pub-id>
<pub-id pub-id-type="pmid">25145752</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-02115">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Husarova</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lakatosova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bakos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vlkova</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Babinska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ostatnikova</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Gastrointestinal microbiota in children with autism in Slovakia</article-title>
<source/>Physiol. Behav.
          <year>2015</year>
<volume>138</volume>
<fpage>179</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2014.10.033</pub-id>
<pub-id pub-id-type="pmid">25446201</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-02115">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Taur</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Walkup</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Gut Microbiota and Autism: Key Concepts and Findings</article-title>
<source/>J. Autism Dev. Disord.
          <year>2017</year>
<volume>47</volume>
<fpage>480</fpage>
<lpage>489</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-016-2960-9</pub-id>
<pub-id pub-id-type="pmid">27882443</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-02115">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hornig</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness</article-title>
<source/>Curr. Opin. Rheumatol.
          <year>2013</year>
<volume>25</volume>
<fpage>488</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1097/BOR.0b013e32836208de</pub-id>
<pub-id pub-id-type="pmid">23656715</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-02115">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naviaux</surname>
<given-names>R.K.</given-names>
</name>
</person-group>
<article-title>Metabolic features of the cell danger response</article-title>
<source/>Mitochondrion
          <year>2014</year>
<volume>16</volume>
<fpage>7</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2013.08.006</pub-id>
<pub-id pub-id-type="pmid">23981537</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-02115">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bauman</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Cho Paik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wick</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jabado</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hirschberg</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Lipkin</surname>
<given-names>W.I.</given-names>
</name>
</person-group>
<article-title>Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<elocation-id>e24585</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0024585</pub-id>
<pub-id pub-id-type="pmid">21949732</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-02115">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van De Sande</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>van Buul</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Brouns</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Autism and nutrition: The role of the gut-brain axis</article-title>
<source/>Nutr. Res. Rev.
          <year>2014</year>
<volume>27</volume>
<fpage>199</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1017/S0954422414000110</pub-id>
<pub-id pub-id-type="pmid">25004237</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-02115">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiorentino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sapone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Senger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Camhi</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Kadzielski</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders</article-title>
<source/>Mol. Autism
          <year>2016</year>
<volume>7</volume>
<fpage>49</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-016-0110-z</pub-id>
<pub-id pub-id-type="pmid">27957319</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-02115">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fond</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Boukouaci</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chevalier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Regnault</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Eberl</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hamdani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Macgregor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dargel</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review</article-title>
<source/>Pathol. Biol. (Paris)
          <year>2015</year>
<volume>63</volume>
<fpage>35</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.patbio.2014.10.003</pub-id>
<pub-id pub-id-type="pmid">25468489</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-02115">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vuong</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>E.Y.</given-names>
</name>
</person-group>
<article-title>Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder</article-title>
<source/>Biol. Psychiatry
          <year>2017</year>
<volume>81</volume>
<fpage>411</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.08.024</pub-id>
<pub-id pub-id-type="pmid">27773355</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-02115">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakefield</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Puleston</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Leary</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Murch</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands</article-title>
<source/>Aliment. Pharmacol. Ther.
          <year>2002</year>
<volume>16</volume>
<fpage>663</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.01206.x</pub-id>
<pub-id pub-id-type="pmid">11929383</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-02115">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>L.H.</given-names>
</name>
</person-group>
<article-title>The role of microbiome in central nervous system disorders</article-title>
<source/>Brain Behav. Immun.
          <year>2014</year>
<volume>38</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2013.12.015</pub-id>
<pub-id pub-id-type="pmid">24370461</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-02115">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaelberer</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Montoya</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bohórquez</surname>
<given-names>D.V.</given-names>
</name>
</person-group>
<article-title>A gut-brain neural circuit for nutrient sensory transduction</article-title>
<source/>Science
          <year>2018</year>
<volume>361</volume>
<fpage>eaat5236</fpage>
<pub-id pub-id-type="doi">10.1126/science.aat5236</pub-id>
<pub-id pub-id-type="pmid">30237325</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-02115">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tellez</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>I.O.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.-W.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X.-B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A Neural Circuit for Gut-Induced Reward</article-title>
<source/>Cell
          <year>2018</year>
<volume>175</volume>
<fpage>665</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.08.049</pub-id>
<pub-id pub-id-type="pmid">30245012</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-02115">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bennuri</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>K.F.</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: A blinded case-control study</article-title>
<source/>PLoS ONE
          <year>2017</year>
<volume>12</volume>
<elocation-id>e0186377</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0186377</pub-id>
<pub-id pub-id-type="pmid">29028817</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-02115">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douglas-Escobar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Neu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Effect of intestinal microbial ecology on the developing brain</article-title>
<source/>JAMA Pediatr.
          <year>2013</year>
<volume>167</volume>
<fpage>374</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1001/jamapediatrics.2013.497</pub-id>
<pub-id pub-id-type="pmid">23400224</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-02115">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulle</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Cubells</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The gut microbiome: a new frontier in autism research</article-title>
<source/>Curr. Psychiatry Rep.
          <year>2013</year>
<volume>15</volume>
<fpage>337</fpage>
<pub-id pub-id-type="doi">10.1007/s11920-012-0337-0</pub-id>
<pub-id pub-id-type="pmid">23307560</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-02115">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>C.S.</given-names>
</name>
</person-group>
<article-title>Microbiome Disturbances and Autism Spectrum Disorders</article-title>
<source/>Drug Metab. Dispos.
          <year>2015</year>
<volume>43</volume>
<fpage>1557</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.115.063826</pub-id>
<pub-id pub-id-type="pmid">25852213</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-02115">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rescigno</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Intestinal microbiota and its effects on the immune system</article-title>
<source/>Cell Microbiol
          <year>2014</year>
<volume>16</volume>
<fpage>1004</fpage>
<lpage>1013</lpage>
<pub-id pub-id-type="doi">10.1111/cmi.12301</pub-id>
<pub-id pub-id-type="pmid">24720613</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-02115">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rook</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Microbiota, immunoregulatory old friends and psychiatric disorders</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2014</year>
<volume>817</volume>
<fpage>319</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4939-0897-4_15</pub-id>
<pub-id pub-id-type="pmid">24997041</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-02115">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>The Central Nervous System and the Gut Microbiome</article-title>
<source/>Cell
          <year>2016</year>
<volume>167</volume>
<fpage>915</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.10.027</pub-id>
<pub-id pub-id-type="pmid">27814521</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-02115">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groer</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Louis-Jacques</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thibeau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>W.A.</given-names>
</name>
</person-group>
<article-title>The very low birth weight infant microbiome and childhood health</article-title>
<source/>Birth Defects Res. C Embryo Today
          <year>2015</year>
<volume>105</volume>
<fpage>252</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1002/bdrc.21115</pub-id>
<pub-id pub-id-type="pmid">26663857</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-02115">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>SM</surname>
<given-names>O.M.</given-names>
</name>
<name>
<surname>Stilling</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The microbiome and childhood diseases: Focus on brain-gut axis</article-title>
<source/>Birth Defects Res. C Embryo Today
          <year>2015</year>
<volume>105</volume>
<fpage>296</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1002/bdrc.21118</pub-id>
<pub-id pub-id-type="pmid">26706413</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-02115">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borre</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>O’Keeffe</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Microbiota and neurodevelopmental windows: implications for brain disorders</article-title>
<source/>Trends Mol. Med.
          <year>2014</year>
<volume>20</volume>
<fpage>509</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2014.05.002</pub-id>
<pub-id pub-id-type="pmid">24956966</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-02115">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Stilling</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Stanton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Collective unconscious: how gut microbes shape human behavior</article-title>
<source/>J. Psychiatr. Res.
          <year>2015</year>
<volume>63</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.02.021</pub-id>
<pub-id pub-id-type="pmid">25772005</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-02115">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borre</surname>
<given-names>Y.E.</given-names>
</name>
<name>
<surname>Moloney</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The impact of microbiota on brain and behavior: mechanisms &amp; therapeutic potential</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2014</year>
<volume>817</volume>
<fpage>373</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4939-0897-4_17</pub-id>
<pub-id pub-id-type="pmid">24997043</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-02115">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rook</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Hygiene and other early childhood influences on the subsequent function of the immune system</article-title>
<source/>Brain Res.
          <year>2015</year>
<volume>1617</volume>
<fpage>47</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.04.004</pub-id>
<pub-id pub-id-type="pmid">24732404</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-02115">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arora</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Dewan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Microbiome: Paediatricians’ perspective</article-title>
<source/>Indian J. Med. Res.
          <year>2015</year>
<volume>142</volume>
<fpage>515</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="doi">10.4103/0971-5916.171275</pub-id>
<pub-id pub-id-type="pmid">26658584</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-02115">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>The impact of gut microbiota on brain and behaviour: implications for psychiatry</article-title>
<source/>Curr. Opin. Clin. Nutr. Metab. Care
          <year>2015</year>
<volume>18</volume>
<fpage>552</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.1097/MCO.0000000000000221</pub-id>
<pub-id pub-id-type="pmid">26372511</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-02115">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohajeri</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Brummer</surname>
<given-names>R.J.M.</given-names>
</name>
<name>
<surname>Rastall</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Weersma</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Harmsen</surname>
<given-names>H.J.M.</given-names>
</name>
<name>
<surname>Faas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eggersdorfer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of the microbiome for human health: From basic science to clinical applications</article-title>
<source/>Eur. J. Nutr.
          <year>2018</year>
<volume>57</volume>
<issue>Suppl. 1</issue>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1007/s00394-018-1703-4</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-02115">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaisas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kanthasamy</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases</article-title>
<source/>Pharmacol. Ther.
          <year>2016</year>
<volume>158</volume>
<fpage>52</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.11.012</pub-id>
<pub-id pub-id-type="pmid">26627987</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-02115">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Borody</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chittick</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khoruts</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Geis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McDonough-Means</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study</article-title>
<source/>Microbiome
          <year>2017</year>
<volume>5</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/s40168-016-0225-7</pub-id>
<pub-id pub-id-type="pmid">28122648</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-02115">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curran</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Dalman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kearney</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Khashan</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Association Between Obstetric Mode of Delivery and Autism Spectrum Disorder: A Population-Based Sibling Design Study</article-title>
<source/>JAMA Psychiatry
          <year>2015</year>
<volume>72</volume>
<fpage>935</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.0846</pub-id>
<pub-id pub-id-type="pmid">26107922</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-02115">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curran</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Kenny</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Kearney</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Khashan</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Obstetrical Mode of Delivery and Childhood Behavior and Psychological Development in a British Cohort</article-title>
<source/>J. Autism Dev. Disord.
          <year>2016</year>
<volume>46</volume>
<fpage>603</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-015-2616-1</pub-id>
<pub-id pub-id-type="pmid">26412364</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-02115">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knight</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Callewaert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Marotz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hyde</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Debelius</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sogin</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>The Microbiome and Human Biology</article-title>
<source/>Annu. Rev. Genomics Hum. Genet.
          <year>2017</year>
<volume>18</volume>
<fpage>65</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-genom-083115-022438</pub-id>
<pub-id pub-id-type="pmid">28375652</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-02115">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stombaugh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lozupone</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Turnbaugh</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The mind-body-microbial continuum</article-title>
<source/>Dialogues Clin. Neurosci.
          <year>2011</year>
<volume>13</volume>
<fpage>55</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">21485746</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-02115">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Labouesse</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Langhans</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Long-term pathological consequences of prenatal infection: beyond brain disorders</article-title>
<source/>Am. J. Physiol. Regul. Integr. Comp. Physiol.
          <year>2015</year>
<volume>309</volume>
<fpage>R1</fpage>
<lpage>R12</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.00087.2015</pub-id>
<pub-id pub-id-type="pmid">25924881</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-02115">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Therapeutic Targets for Neurodevelopmental Disorders Emerging from Animal Models with Perinatal Immune Activation</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>28218</fpage>
<lpage>28229</lpage>
<pub-id pub-id-type="doi">10.3390/ijms161226092</pub-id>
<pub-id pub-id-type="pmid">26633355</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-02115">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazaro</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Ponde</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Opioid peptides and gastrointestinal symptoms in autism spectrum disorders</article-title>
<source/>Rev. Bras. Psiquiatr.
          <year>2016</year>
<volume>38</volume>
<fpage>243</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="doi">10.1590/1516-4446-2015-1777</pub-id>
<pub-id pub-id-type="pmid">27304256</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-02115">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cavalieri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Donati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jousson</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Renzi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Calabro</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New evidences on the altered gut microbiota in autism spectrum disorders</article-title>
<source/>Microbiome
          <year>2017</year>
<volume>5</volume>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.1186/s40168-017-0242-1</pub-id>
<pub-id pub-id-type="pmid">28222761</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-02115">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Hornig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parekh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lipkin</surname>
<given-names>W.I.</given-names>
</name>
</person-group>
<article-title>Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances</article-title>
<source/>mBio
          <year>2012</year>
<volume>3</volume>
<fpage>e00261-11</fpage>
<pub-id pub-id-type="doi">10.1128/mBio.00261-11</pub-id>
<pub-id pub-id-type="pmid">22233678</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-02115">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushak</surname>
<given-names>R.I.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>N.L.</given-names>
</name>
</person-group>
<article-title>Analysis of the Duodenal Microbiome in Autistic Individuals: Association With Carbohydrate Digestion</article-title>
<source/>J. Pediatr. Gastroenterol. Nutr.
          <year>2017</year>
<volume>64</volume>
<fpage>e110</fpage>
<lpage>e116</lpage>
<pub-id pub-id-type="doi">10.1097/MPG.0000000000001458</pub-id>
<pub-id pub-id-type="pmid">27811623</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-02115">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mazmanian</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Tillisch</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Gut microbes and the brain: paradigm shift in neuroscience</article-title>
<source/>J. Neurosci.
          <year>2014</year>
<volume>34</volume>
<fpage>15490</fpage>
<lpage>15496</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3299-14.2014</pub-id>
<pub-id pub-id-type="pmid">25392516</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-02115">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gondalia</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Palombo</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings</article-title>
<source/>Autism Res.
          <year>2012</year>
<volume>5</volume>
<fpage>419</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1002/aur.1253</pub-id>
<pub-id pub-id-type="pmid">22997101</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-02115">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Rowehl</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Litcher-Kelly</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gadow</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Gathungu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>C.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of Fecal Microbiota in Children with Autism Spectrum Disorders and Neurotypical Siblings in the Simons Simplex Collection</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0137725</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0137725</pub-id>
<pub-id pub-id-type="pmid">26427004</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-02115">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Does the human gut microbiota contribute to the etiology of autism spectrum disorders?</article-title>
<source/>Dig. Dis. Sci.
          <year>2012</year>
<volume>57</volume>
<fpage>1987</fpage>
<lpage>1989</lpage>
<pub-id pub-id-type="doi">10.1007/s10620-012-2286-1</pub-id>
<pub-id pub-id-type="pmid">22736019</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-02115">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argou-Cardozo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zeidan-Chulia</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Clostridium Bacteria and Autism Spectrum Conditions: A Systematic Review and Hypothetical Contribution of Environmental Glyphosate Levels</article-title>
<source/>Med. Sci.
          <year>2018</year>
<volume>6</volume>
<elocation-id>29</elocation-id>
<pub-id pub-id-type="doi">10.3390/medsci6020029</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-02115">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantarcioglu</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Kiraz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Microbiota-Gut-Brain Axis: Yeast Species Isolated from Stool Samples of Children with Suspected or Diagnosed Autism Spectrum Disorders and In Vitro Susceptibility Against Nystatin and Fluconazole</article-title>
<source/>Mycopathologia
          <year>2016</year>
<volume>181</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1007/s11046-015-9949-3</pub-id>
<pub-id pub-id-type="pmid">26442855</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-02115">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weston</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fogal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dhurjati</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>An agent-based modeling framework for evaluating hypotheses on risks for developing autism: effects of the gut microbial environment</article-title>
<source/>Med. Hypotheses
          <year>2015</year>
<volume>84</volume>
<fpage>395</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2015.01.027</pub-id>
<pub-id pub-id-type="pmid">25670416</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-02115">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heberling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dhurjati</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Novel systems modeling methodology in comparative microbial metabolomics: identifying key enzymes and metabolites implicated in autism spectrum disorders</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>8949</fpage>
<lpage>8967</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16048949</pub-id>
<pub-id pub-id-type="pmid">25913376</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-02115">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grimaldi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cela</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Vulevic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Tzortzis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Costabile</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>In vitro fermentation of B-GOS: impact on faecal bacterial populations and metabolic activity in autistic and non-autistic children</article-title>
<source/>FEMS Microbiol. Ecol.
          <year>2017</year>
<volume>93</volume>
<pub-id pub-id-type="doi">10.1093/femsec/fiw233</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-02115">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Urinary 3-(3-Hydroxyphenyl)-3-hydroxypropionic Acid, 3-Hydroxyphenylacetic Acid, and 3-Hydroxyhippuric Acid Are Elevated in Children with Autism Spectrum Disorders</article-title>
<source/>Biomed. Res. Int.
          <year>2016</year>
<volume>2016</volume>
<fpage>9485412</fpage>
<pub-id pub-id-type="doi">10.1155/2016/9485412</pub-id>
<pub-id pub-id-type="pmid">27123458</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-02115">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clayton</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Metabolic differences underlying two distinct rat urinary phenotypes, a suggested role for gut microbial metabolism of phenylalanine and a possible connection to autism</article-title>
<source/>FEBS Lett.
          <year>2012</year>
<volume>586</volume>
<fpage>956</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2012.01.049</pub-id>
<pub-id pub-id-type="pmid">22306194</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-02115">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gevi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zolla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gabriele</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism</article-title>
<source/>Mol. Autism
          <year>2016</year>
<volume>7</volume>
<fpage>47</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-016-0109-5</pub-id>
<pub-id pub-id-type="pmid">27904735</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-02115">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Targeting gut microbiome: A novel and potential therapy for autism</article-title>
<source/>Life Sci.
          <year>2018</year>
<volume>194</volume>
<fpage>111</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2017.12.027</pub-id>
<pub-id pub-id-type="pmid">29277311</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-02115">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasquez</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Biological plausibility of the gut-brain axis in autism</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <year>2017</year>
<volume>1408</volume>
<fpage>5</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1111/nyas.13516</pub-id>
<pub-id pub-id-type="pmid">29090837</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-20-02115">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Angley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Veselkov</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lindon</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls</article-title>
<source/>J. Proteome Res.
          <year>2010</year>
<volume>9</volume>
<fpage>2996</fpage>
<lpage>3004</lpage>
<pub-id pub-id-type="doi">10.1021/pr901188e</pub-id>
<pub-id pub-id-type="pmid">20337404</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-20-02115">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lees</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Hippurate: the natural history of a mammalian-microbial cometabolite</article-title>
<source/>J. Proteome Res.
          <year>2013</year>
<volume>12</volume>
<fpage>1527</fpage>
<lpage>1546</lpage>
<pub-id pub-id-type="doi">10.1021/pr300900b</pub-id>
<pub-id pub-id-type="pmid">23342949</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-20-02115">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Angelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Francavilla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Piccolo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Giacomo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gobbetti</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorders and intestinal microbiota</article-title>
<source/>Gut Microbes
          <year>2015</year>
<volume>6</volume>
<fpage>207</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1080/19490976.2015.1035855</pub-id>
<pub-id pub-id-type="pmid">25835343</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-20-02115">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wynendaele</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Verbeke</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stalmans</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gevaert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Van De Wiele</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peremans</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Burvenich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Spiegeleer</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Quorum Sensing Peptides Selectively Penetrate the Blood-Brain Barrier</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0142071</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0142071</pub-id>
<pub-id pub-id-type="pmid">26536593</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-20-02115">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marler</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>McDonnell</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brief Report: Whole Blood Serotonin Levels and Gastrointestinal Symptoms in Autism Spectrum Disorder</article-title>
<source/>J. Autism Dev. Disord.
          <year>2016</year>
<volume>46</volume>
<fpage>1124</fpage>
<lpage>1130</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-015-2646-8</pub-id>
<pub-id pub-id-type="pmid">26527110</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-20-02115">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reardon</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Gut-brain link grabs neuroscientists</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>175</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1038/515175a</pub-id>
<pub-id pub-id-type="pmid">25391939</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-20-02115">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jory</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Abnormal fatty acids in Canadian children with autism</article-title>
<source/>Nutrition
          <year>2016</year>
<volume>32</volume>
<fpage>474</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2015.10.019</pub-id>
<pub-id pub-id-type="pmid">26746679</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-20-02115">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiser</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Butt</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Mohajeri</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Docosahexaenoic Acid and Cognition throughout the Lifespan</article-title>
<source/>Nutrients
          <year>2016</year>
<volume>8</volume>
<elocation-id>99</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu8020099</pub-id>
<pub-id pub-id-type="pmid">26901223</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-20-02115">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anwar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abruzzo</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Bolotta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ghezzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Visconti</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thornalley</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Rabbani</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls</article-title>
<source/>Free Radic. Res.
          <year>2016</year>
<volume>50</volume>
<fpage>S85</fpage>
<lpage>S90</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2016.1239821</pub-id>
<pub-id pub-id-type="pmid">27667096</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-20-02115">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangiola</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ianiro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fagiuoli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gasbarrini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gasbarrini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Gut microbiota in autism and mood disorders</article-title>
<source/>World J. Gastroenterol
          <year>2016</year>
<volume>22</volume>
<fpage>361</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v22.i1.361</pub-id>
<pub-id pub-id-type="pmid">26755882</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-20-02115">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pifer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sperandio</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The Interplay between the Microbiota and Enterohemorrhagic Escherichia coli</article-title>
<source/>Microbiol. Spectr.
          <year>2014</year>
<volume>2</volume>
<pub-id pub-id-type="doi">10.1128/microbiolspec.EHEC-0015-2013</pub-id>
<pub-id pub-id-type="pmid">26104352</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-20-02115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aw</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Toward the comprehensive understanding of the gut ecosystem via metabolomics-based integrated omics approach</article-title>
<source/>Semin. Immunopathol.
          <year>2015</year>
<volume>37</volume>
<fpage>5</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1007/s00281-014-0456-2</pub-id>
<pub-id pub-id-type="pmid">25338280</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-20-02115">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vacy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>W.C.</given-names>
</name>
</person-group>
<article-title>Fatty acids and their therapeutic potential in neurological disorders</article-title>
<source/>Neurochem. Int.
          <year>2016</year>
<volume>95</volume>
<fpage>75</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2016.02.014</pub-id>
<pub-id pub-id-type="pmid">26939763</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-20-02115">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet</article-title>
<source/>J. Agric. Food Chem.
          <year>2015</year>
<volume>63</volume>
<fpage>7885</fpage>
<lpage>7895</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jafc.5b02404</pub-id>
<pub-id pub-id-type="pmid">26306709</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-20-02115">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borghi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Borgo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Severgnini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Savini</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Casiraghi</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Vignoli</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Rett Syndrome: A Focus on Gut Microbiota</article-title>
<source/>Int. J. Mol. Sci.
          <year>2017</year>
<volume>18</volume>
<elocation-id>344</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms18020344</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-20-02115">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frye</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chacko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wynne</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bennuri</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Tippett</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delhey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Melnyk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>S.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines</article-title>
<source/>Transl. Psychiatry
          <year>2016</year>
<volume>6</volume>
<fpage>e927</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2016.189</pub-id>
<pub-id pub-id-type="pmid">27779624</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-20-02115">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slattery</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>MacFabe</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?</article-title>
<source/>Curr. Pharm. Des.
          <year>2016</year>
<volume>22</volume>
<fpage>6107</fpage>
<lpage>6121</lpage>
<pub-id pub-id-type="doi">10.2174/1381612822666160905123953</pub-id>
<pub-id pub-id-type="pmid">27592717</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-20-02115">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohajeri</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>La Fata</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Steinert</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Relationship between the gut microbiome and brain function</article-title>
<source/>Nutr. Rev.
          <year>2018</year>
<volume>76</volume>
<fpage>481</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1093/nutrit/nuy009</pub-id>
<pub-id pub-id-type="pmid">29701810</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-20-02115">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rinaldi</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Piecing together a different picture: A host of new studies on autism have begun decoding the longstanding puzzle of its causes</article-title>
<source/>EMBO Rep.
          <year>2016</year>
<volume>17</volume>
<fpage>1690</fpage>
<lpage>1695</lpage>
<pub-id pub-id-type="doi">10.15252/embr.201643502</pub-id>
<pub-id pub-id-type="pmid">27856535</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-20-02115">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beales</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Biome depletion in conjunction with evolutionary mismatches could play a role in the etiology of neurofibromatosis 1</article-title>
<source/>Med. Hypotheses
          <year>2015</year>
<volume>84</volume>
<fpage>305</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2015.01.014</pub-id>
<pub-id pub-id-type="pmid">25665856</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-20-02115">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sakaue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sawai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sawai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ozeki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Romero-Perez</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Tsukahara</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>A preliminary investigation on the relationship between gut microbiota and gene expressions in peripheral mononuclear cells of infants with autism spectrum disorders</article-title>
<source/>Biosci. Biotechnol. Biochem.
          <year>2016</year>
<volume>80</volume>
<fpage>2450</fpage>
<lpage>2458</lpage>
<pub-id pub-id-type="doi">10.1080/09168451.2016.1222267</pub-id>
<pub-id pub-id-type="pmid">27581276</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-20-02115">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diaz-Gerevini</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Repossi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dain</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tarres</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>U.N.</given-names>
</name>
<name>
<surname>Eynard</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Beneficial action of resveratrol: How and why?</article-title>
<source/>Nutrition
          <year>2016</year>
<volume>32</volume>
<fpage>174</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2015.08.017</pub-id>
<pub-id pub-id-type="pmid">26706021</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-20-02115">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Fata</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rastall</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Lacroix</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Harmsen</surname>
<given-names>H.J.M.</given-names>
</name>
<name>
<surname>Mohajeri</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Steinert</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Recent Development of Prebiotic Research-Statement from an Expert Workshop</article-title>
<source/>Nutrients
          <year>2017</year>
<volume>9</volume>
<elocation-id>1376</elocation-id>
<pub-id pub-id-type="doi">10.3390/nu9121376</pub-id>
<pub-id pub-id-type="pmid">29261110</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-20-02115">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherwin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sandhu</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Dinan</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>May the Force Be With You: The Light and Dark Sides of the Microbiota-Gut-Brain Axis in Neuropsychiatry</article-title>
<source/>CNS Drugs
          <year>2016</year>
<volume>30</volume>
<fpage>1019</fpage>
<lpage>1041</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-016-0370-3</pub-id>
<pub-id pub-id-type="pmid">27417321</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-20-02115">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umbrello</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Microbiota and neurologic diseases: potential effects of probiotics</article-title>
<source/>J. Transl. Med.
          <year>2016</year>
<volume>14</volume>
<fpage>298</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-016-1058-7</pub-id>
<pub-id pub-id-type="pmid">27756430</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-20-02115">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aroniadis</surname>
<given-names>O.C.</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation: past, present and future</article-title>
<source/>Curr. Opin. Gastroenterol.
          <year>2013</year>
<volume>29</volume>
<fpage>79</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1097/MOG.0b013e32835a4b3e</pub-id>
<pub-id pub-id-type="pmid">23041678</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-20-02115">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrof</surname>
<given-names>E.O.</given-names>
</name>
<name>
<surname>Claud</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Gloor</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Allen-Vercoe</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Microbial ecosystems therapeutics: a new paradigm in medicine?</article-title>
<source/>Benef. Microbes
          <year>2013</year>
<volume>4</volume>
<fpage>53</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.3920/BM2012.0039</pub-id>
<pub-id pub-id-type="pmid">23257018</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-20-02115">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ianiro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bibbo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gasbarrini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cammarota</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Therapeutic modulation of gut microbiota: Current clinical applications and future perspectives</article-title>
<source/>Curr. Drug Targets
          <year>2014</year>
<volume>15</volume>
<fpage>762</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.2174/1389450115666140606111402</pub-id>
<pub-id pub-id-type="pmid">24909808</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-20-02115">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skosnik</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Cortes-Briones</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Targeting the ecology within: The role of the gut-brain axis and human microbiota in drug addiction</article-title>
<source/>Med. Hypotheses
          <year>2016</year>
<volume>93</volume>
<fpage>77</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2016.05.021</pub-id>
<pub-id pub-id-type="pmid">27372861</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-20-02115">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteley</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Nutritional management of (some) autism: A case for gluten- and casein-free diets?</article-title>
<source/>Proc. Nutr. Soc.
          <year>2015</year>
<volume>74</volume>
<fpage>202</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1017/S0029665114001475</pub-id>
<pub-id pub-id-type="pmid">25311313</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-20-02115">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfawaz</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>El-Ansary</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Protective and restorative potency of Vitamin D on persistent biochemical autistic features induced in propionic acid-intoxicated rat pups</article-title>
<source/>BMC Complement. Altern. Med.
          <year>2014</year>
<volume>14</volume>
<elocation-id>416</elocation-id>
<pub-id pub-id-type="doi">10.1186/1472-6882-14-416</pub-id>
<pub-id pub-id-type="pmid">25344727</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-20-02115">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mental health: thinking from the gut</article-title>
<source/>Nature
          <year>2015</year>
<volume>518</volume>
<fpage>S12</fpage>
<lpage>S15</lpage>
<pub-id pub-id-type="doi">10.1038/518S13a</pub-id>
<pub-id pub-id-type="pmid">25715275</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-20-02115">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashida</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Furuhara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamauchi</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Deguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Harashima</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munesue</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lopatina</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gerasimenko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Salmina</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intestinal transepithelial permeability of oxytocin into the blood is dependent on the receptor for advanced glycation end products in mice</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>7883</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-07949-4</pub-id>
<pub-id pub-id-type="pmid">28801574</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-02115-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Methodical approach of this systematic review due to PRISMA criteria [<xref ref-type="bibr" rid="B39-ijms-20-02115">39</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-02115-g001"></graphic>
</fig>
<fig id="ijms-20-02115-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Co-occurring pathologies found in Autism Spectrum disorder (ASD). Red shows gut-related comorbidities found in ASD, purple shows brain-related comorbidities and orange other comorbidities. Chapter 3 gives more information to the mentioned comorbidities.</p>
</caption>
<graphic xlink:href="ijms-20-02115-g002"></graphic>
</fig>
<fig id="ijms-20-02115-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Taxonomic classification of dysbiotic bacteria found in autistic individuals. All bacterial taxa mentioned within this chapter are found in this figure. Green indicates elevated taxa in the gut microbiota of ASD individuals. Red indicates decreased taxa in the gut microbiota ASD individuals. Additionally, black surrounded boxes show significant results in at least one study. Significance levels are taken from the original literature.</p>
</caption>
<graphic xlink:href="ijms-20-02115-g003"></graphic>
</fig>
<fig id="ijms-20-02115-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Process of <italic>Clostridium tetani</italic> infection in the gut. Occurrence of the bacterium <italic>Clostridium tetani</italic> in the GI tract of autistic population could lead to altered behaviour. [<xref ref-type="bibr" rid="B43-ijms-20-02115">43</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-02115-g004"></graphic>
</fig>
<fig id="ijms-20-02115-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Metabolic pathways of tryptophan. The purple pathways show human metabolism of tryptophan and the orange pathways are observed in bacterial degradation. Green surrounded boxes show elevated metabolites and red surrounded boxes show decreased metabolites in the autistic metabolome [<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>].</p>
</caption>
<graphic xlink:href="ijms-20-02115-g005"></graphic>
</fig>
<table-wrap id="ijms-20-02115-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-02115-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Elevated and decreased metabolites in the urinary profiles of ASD children. Significant results are written in bold.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#C2D69B" valign="middle">Elevated Urinary Metabolites in ASD Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#C2D69B" valign="middle">
</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#D99594" valign="middle">Decreased Urinary Metabolites in ASD Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#D99594" valign="middle">
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic>N</italic>-methyl-2-pyridone-5-carboxamide</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Glutamate</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic>N</italic>-methyl nicotinic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Hippurate</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic>N</italic>-methyl nicotinamide</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Phenylacetylglutamine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic>N</italic>-acetyl glycoprotein fragments</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Succinate</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Melatonin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Acetate</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Kynurenic acid</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Taurine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Dimethylamine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B105-ijms-20-02115">105</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>3-(3-hydroxyphenyl)-3-hydroxypropionic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>3-hydroxyphenylacetic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>3-hydroxyhippuric acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B99-ijms-20-02115">99</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tryptophan degradation products</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Xanthurenic acid</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Quinolinic acid</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Indolyl-3-acetic</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Indolyl-lactate</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><italic>P</italic>-cresol</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B101-ijms-20-02115">101</xref>,<xref ref-type="bibr" rid="B102-ijms-20-02115">102</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TNF-α</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Free amino acids</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B40-ijms-20-02115">40</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sulphate, sulphite, thiosulphate</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-20-02115-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-02115-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Summary of statistically significantly elevated and decreased metabolites in the blood of autistic patients. Major bacteria responsible for the elevated metabolites are given in parentheses.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#C2D69B" valign="middle">Elevated Metabolites in the Blood of ASD Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#C2D69B" valign="middle">
</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#D99594" valign="middle">Decreased Metabolites in the Blood of ASD Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#D99594" valign="middle">
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Serotonin (Candida, Streptococcus, Escherichia and Enterococcus spp)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B108-ijms-20-02115">108</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Methionine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>GABA (Lactobacillus and Bifidobacterium spp)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B98-ijms-20-02115">98</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>S-adenosylmethionine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic>p</italic>-cresol (Clostridia spp)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Homocysteine</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Lipopolysaccharides (gram negative bacteria)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B56-ijms-20-02115">56</xref>,<xref ref-type="bibr" rid="B113-ijms-20-02115">113</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Glutathione</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B104-ijms-20-02115">104</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Docosahexaenoic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B110-ijms-20-02115">110</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Eicosapentaenoic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B110-ijms-20-02115">110</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Arachidonic acid</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B110-ijms-20-02115">110</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Thiamine-pyrophosphate</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B112-ijms-20-02115">112</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-20-02115-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-02115-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Non-exhaustive list of reports studying the effects of probiotics supplementation in ASD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid #FDE4D0" valign="middle">Probiotic Used</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid #FDE4D0" valign="middle">Effects</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid #FDE4D0" valign="middle">Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">
<bold>Children Dophilus (Bifidobacterium, Lactobacillus, Streptococcus spp)</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">Amelioration of Firmicutes to Bacteroidetes ratio</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">Humans [<xref ref-type="bibr" rid="B49-ijms-20-02115">49</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Lactobacillus rhamnosus, Bifidobacterium infantis, Bifidobacterium longus, Lactobacillus helveticus, Lactobacillus reuteri and Lactobacillus paracasei</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improvement of GI problems</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Humans [<xref ref-type="bibr" rid="B106-ijms-20-02115">106</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">
<bold>Lactobacillus reuteri</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">- Reversing inflammation caused through lipopolysaccharides<break></break>- Stimulating the production of Oxytocin</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">Rats [<xref ref-type="bibr" rid="B46-ijms-20-02115">46</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<bold>Bifidobacterium spp</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Elevation of arachidonic and docosahexaenoic acid concentration in the brain</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Mice [<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">
<bold>Lactobacillus rhamnosus</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">- Reduction of corticosterone levels<break></break>- Alterations of GABA levels</td>
<td align="center" colspan="1" rowspan="1" style="background:#FDE4D0" valign="middle">Mice [<xref ref-type="bibr" rid="B117-ijms-20-02115">117</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Bacteroides fragilis</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">- Improvement of autistic features<break></break>- Correction of tight junction proteins expression in the colon</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mice [<xref ref-type="bibr" rid="B5-ijms-20-02115">5</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>